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1. Introduction 
1.1. Major Depressive Disorder (MDD) 
According to the World Health Organization (WHO) depressive disorders are of outstanding 
health-economic importance as they are the psychiatric disorders that most frequently cause 
psychosocial disability (WHO 2017). Intensive biologically oriented psychiatric research over 
the last decades contributed to a deeper insight in miscellaneous pathophysiologic mechanisms 
playing a role in the etiology of Major Depressive Disorder (MDD) (Schüle, Baghai et al. 2007). 
Nevertheless, the etiology of depressive disorders still is not fully understood. A multifactorial 
genesis is supposed and has been elucidated in increasing detail. Besides psychological and 
social factors biological variables apparently play a major role, which lead in their whole to a 
disturbed central nervous homeostasis. MDD is a chronic stress related disorder and a complex 
clinical syndrome characterized not only by depressed mood but also by vegetative and 
cognitive symptoms. Moreover, genetic, neuroendocrine and neurochemical biomarkers may 
predict impaired processing and regulation of emotions related to major depression as well as 
antidepressant treatment response in general. In patients suffering from acute depression a wide 
range of negative influence on the processing of emotional information is manifested. This is 
believed to contribute to the etiology and maintenance of the depressed state (Beck 2008). 
1.2. HPA axis activity 
A dysregulation of the activity of the hypothalamic-pituitary-adrenocortical (HPA) system is 
one of the major neuroendocrine abnormalities in major depressive disorder (Holsboer and 
Barden 1996). These include elevated circulating plasma levels of both corticotropin 
(adrenocorticotropic hormone, ACTH) and cortisol (Holsboer and Barden 1996) in addition 
with elevated levels of corticotropin releasing hormone (CRH) in the cerebrospinal fluid 
(Nemeroff, Widerlov et al. 1984). One of the first neuroendocrine function tests investigating 
HPA axis dysregulation in depression was the dexamethasone suppression test (DST). In 
contrast to the suppressibility of ACTH and cortisol secretion after administration of the 
synthetic glucocorticoid dexamethasone (Dex) in healthy volunteers there was an enhanced 
proportion of patients suffering from affective disorders with escape from adequate cortisol 
suppression (Carroll 1982). In addition, a change of the DST results in dependency from the 
clinical outcome was described (Greden, Gardner et al. 1983). In contrast to the DST the 
combined dexamethasone suppression / corticotropin releasing hormone stimulation 
(Dex/CRH) test seems to be an even better and more sensitive diagnostic tools for the 
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assessment of the HPA system dysregulation in depression available so far. A test sensitivity 
of 80 up to 90% has been shown in depressed patients (Heuser, Yassouridis et al. 1994). It has 
been suggested that the hyperactivity of the HPA system during depression may be considered 
as a neuroendocrine sign of a disturbed HPA system homeostasis which is rather used as a state 
than as a trait marker of diagnostic entities (Heuser, Yassouridis et al. 1994). Despite partly 
conflicting results, the amygdala and the hippocampus seem to have faciliatory or regulatory 
roles in the generation of HPA axis responses, at least this was shown in animal experiments 
(Goursaud, Mendoza et al. 2006). Also, a relationship between hypercortisolemia and cognitive 
dysfunction in acutely depressed patients has been published some years ago (Behnken, 
Bellingrath et al. 2013). An involvement of the amygdala in the processing of facial emotional 
expressions such as anger, sadness and disgust was hypothesized. Porter and Gallagher 
described a dysfunction of monoaminergic transmitter systems in depression including 
cognitive impairment which is facilitated by the HPA-system (Porter and Gallagher 2006). 
Adolphs described an activation of the HPA system during the perception of fear. This results 
in an activation of the hypothalamus after perception of the threatening emotional information 
by projection of the stress-signaling impulses via the amygdala (Adolphs 2008). Thus, it is still 
discussed, whether the specific role of the amygdala is only the processing of fear or whether it 
is responsible for the accurate identification of facial emotional expressions in general 
(Loughead, Gur et al. 2008). There exists strong evidence for the very important role of the 
amygdala in regulating the response of the HPA axis to stress, but also to positive emotional 
faces (van Marle, Hermans et al. 2009), although the exact kind of emotion processing by the 
amygdala is less clear up to now (Ellenbogen, Carson et al. 2010). In MDD both types of 
processing are abnormal, HPA axis function (investigated using the DST) and facial emotion 
processing (Maes, Calabrese et al. 1994). Patients suffering from MDD demonstrate a biased 
and increased attention during the processing of negative facial expressions (Bourke, Douglas 
et al. 2010). This seems to be true even for non-affected high risk probands for depression, in 
first-degree relatives of patients with MDD who – in addition – show an elevated HPA axis 
activity (Ising, Lauer et al. 2005, Le Masurier, Cowen et al. 2007). Therefore, in depression an 
interdependency between the perception of emotional facial expressions and the HPA-axis 
regulation, which in turn appears to be influenced by major depression, has been confirmed by 
these earlier studies. 
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1.3. Antidepressant treatment 
1.3.1. Antidepressants 
A multifactorial genesis of MDD is supposed and has been elucidated in increasing detail during 
the last years. Accordingly, treatment of depression uses also multilayer approaches. In case of 
moderate depression national and international guidelines recommend either antidepressants or 
psychotherapy respectively, in case of severe or treatment resistant depression both approaches 
are recommended (DGPPN 2015). In case of medium to severe depression the combination of 
antidepressants with psychotherapy, psychoeducation and social support is associated with the 
highest probability of a fast response to the treatment. 
Over the last decades, our understanding of the neurochemical mechanisms of antidepressant 
drug action has advanced considerably, but, although the knowledge about the 
pharmacodynamic mechanisms of action of antidepressants increased steadily, there is still a 
lack of information about the exact mechanisms of action in the human brain and which of these 
are mandatory for the antidepressant efficacy. Moreover, it remains to be elucidated, how far 
changes in emotional processing may account for the resolution of this multiple symptom 
domains during successful treatment with antidepressants. Recent fMRI neuroimaging studies 
suggest that a change in emotional processing could also explain partly the global improvement 
because attention and appraisal are of fundamental importance in brain function. The influence 
of antidepressant treatments on HPA axis activity and the potential to predict treatment response 
with repeated Dex/CRH tests are well known (Schule, Baghai et al. 2009), nevertheless, it 
remains unclear up to now whether the activity in central areas such as amygdala or 
hippocampus or other brain regions have the potential to contribute to an earlier and more 
reliable prediction of treatment effects. For some classes of antidepressants, e.g. for selective 
serotonin reuptake inhibitors (SSRIs) changes in the emotion processing circuitry and area 
specific changes in the brain activation were associated with treatment response (Anderson, 
McKie et al. 2008) or efficacy (Cipriani, Furukawa et al. 2009). However, most pharmaco-
fMRI studies deduced effects in brain activation by antidepressants from the investigation in 
healthy subjects, not in depressed patients who showed dysfunctions in emotional and cognitive 
processing in the brain associated with depressive disorders (Akimova, Lanzenberger et al. 
2009, Lanzenberger, Wadsak et al. 2010). A huge number of studies have considered the effect 
of a single dose of an SSRI on emotional processing. These data are useful in addressing the 
following issue: Overall, it appears that a single dose of the SSRI (e.g. citalopram) can result in 
increased fear recognition and increased emotion potentiated startle response (Harmer, 
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Bhagwagar et al. 2003, Browning, Reid et al. 2007, Grillon, Levenson et al. 2007). Importantly, 
in addition to this anxiogenic-like effect, positive changes in emotional bias are also observed 
in single dose studies, in terms of attentional bias to positive words (Browning, Reid et al. 2007) 
and increased recognition of happy faces (Harmer, Bhagwagar et al. 2003). This suggests that 
a single administration of an SSRI produces a mixture of negative and positive emotional effects 
in cognitive models. However, after seven days of SSRI treatment there is evidence for a 
decreased fear response in term of diminished recognition of fearful faces and reduced 
emotional startle reaction (Harmer, Shelley et al. 2004). This fits well with the clinical 
observation that acutely administered SSRIs may first increase anxiety, while repeated 
treatment has sustained anxiolytic effects. 
There is a growing body of evidence that antidepressants can affect emotional processing very 
early after starting the treatment and independently from changes in subjective mood. For 
example, after a one-week treatment with the SSRI citalopram or the selective noradrenaline 
reuptake inhibitor (NARI) reboxetine in healthy volunteers a change in emotional processing 
could be seen which indicated responses in the opposite direction of the changes seen generally 
in depressive disorders (Harmer, Shelley et al. 2004). Moreover, according to studies in healthy 
volunteers, antidepressant drugs have some effects on emotional processing very quickly after 
administration in the absence of discernible changes in mood. One study shows that short term 
SSRI treatment was associated with reduced blood oxygenation level-dependent (BOLD) 
response in the amygdala to negative facial expressions presented outside of conscious 
awareness (Harmer, Mackay et al. 2006). Such a finding suggests thinking about the role of the 
amygdala in antidepressant treatment, because the amygdala plays a key role in the processing 
of threat or fear-relevant cues as described before. 
Taken together, findings from the single dose and seven-day pharmaco-fMRI studies with 
antidepressants in healthy volunteers indicate that cognitive models of antidepressant drug 
action reveal positive changes in emotional processing. A reversible increase in negative 
emotional processing can be found very early after initiation of the treatment, which is in line 
with clinical observations of early, but reversible increase of anxiety after starting an SSRI 
treatment, whereas positive effects can be found to be sustained. 
As described before, it seems that CRH levels are in relationship with amygdala hyperactivity 
in MDD patients, because MDD is accompanied by both cognitive impairment and a 
hyperactivity of the HPA system, resulting in an enhanced glucocorticoid secretion. Cortisol 
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acts via mineralocorticoid and glucocorticoid receptors densely located in the hippocampus, a 
brain area that is important regarding cognitive functions and especially memory functions. 
Antidepressants such as SSRIs can influence emotional processing very early on during the 
treatment and independently from changes in subjective mood. On the other hand, hyperactivity 
of the hypothalamic-pituitary-adrenal (HPA) axis in MDD is one of the most reliably reported 
neurobiological characteristics of affective disorders. Whether these alterations in HPA axis 
regulation are limited to the acute stage of MDD or whether they persist after recovery, at least 
in some patients, remains ambiguous. A relationship between hypercortisolemia and cognitive 
dysfunction in acutely depressed patients has been repeatedly observed and it was also 
demonstrated in several studies that a discrete cognitive impairment often persists in the 
remitted state of depression (Behnken, Bellingrath et al. 2013). On the other hand, MDD is 
accompanied by morphological changes of brain structures like the hippocampus and the 
amygdala which are of great importance in the neural circuitry mediating depression. 
Hyperactivity of the HPA system resulting in enhanced glucocorticoid secretion can often be 
observed during depression and has been thought to play an important role in inducing these 
morphological changes (Schuhmacher, Mossner et al. 2012). The SSRI (es)citalopram, used 
frequently as a first line treatment of MDD, influenced emotional processing shortly after the 
start of treatment (Harmer, Bhagwagar et al. 2003, Browning, Reid et al. 2007) as described 
before. Also studies with mirtazapine, an 2-adrenoreceptor blocker with additional influence 
on histaminic H1-, 5HT2a-, 5HT2c-, and 5HT3-receptors, resulted in a reduction of emotional 
fear processing: a significantly impaired recognition of fearful facial expressions and reduced 
eye-blink responses in the emotion potentiated startle task, an effect similar to that of SSRIs, 
was reported (Arnone, Horder et al. 2009, Komulainen, Heikkila et al. 2016). Agomelatine 
attenuated fMRI activations in several regions involved in face processing (fusiform gyrus, 
bilateral inferior frontal gyrus, anterior thalamic nucleus) and showed an antidepressant-like 
ability to modulate early visual processing of faces in healthy controls without affecting 
amygdala responses (Lees J 2010). In depressed patients, agomelatine had short- and long-term 
effects on brain structures involved in emotional regulation such as the dorsomedial prefrontal 
cortex and precuneus. The development of corresponding biomarkers for a biomarker-based 
treatment of MDD was suggested (Delaveau, Jabourian et al. 2016). Agomelatine is the first 
antidepressant with a thus far unique mode of action. It acts as an agonist at melatonin MT1 and 
MT2 receptors in combination with 5HT2c-antagonistic properties. Randomized double-blind 
placebo-controlled clinical studies showed an antidepressant and anxiolytic efficacy of 
agomelatine in the treatment of patients suffering from MDD (Kennedy and Emsley 2006, Olie 
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and Kasper 2007) and anxiety disorders (for review see: (Eser, Baghai et al. 2007)). MDD 
patients displayed greater amygdala activation when anticipating negative pictures and greater 
prefrontal activation when confronted with them without the anticipatory cues. After 
antidepressant treatment, both amygdala and prefrontal activation decreased significantly in the 
treated MDD patients relative to controls. These findings show that the neural mechanisms of 
emotional anticipation and processing are altered in patients with MDD and that the functional 
neuroanatomy of emotional processing is normalized after successful treatment with an 
antidepressant (Rosenblau, Sterzer et al. 2012). 
1.3.2. Psychotherapy 
There are a number of studies investigating neural activation after treatment with 
antidepressants, but only a very limited number of fMRI studies investigating the effects of 
psychotherapy on the processing of facial emotions can be found. Fu et al. investigated the 
neural correlates of implicit processing of sad facial expressions in depression before and after 
16 weeks of weekly Cognitive Behavioral Therapy (CBT) treatment. Elevated amygdala-
hippocampal activity in patients compared to healthy individuals could be demonstrated 
following therapy. In addition, the dorsal anterior cingulate activity showed a significant 
relationship with the post-treatment clinical response in depressed patients (Fu, Williams et al. 
2008). Also, Siegle et al. could show a changed amygdala activity after psychotherapy. Their 
patients were treated successfully with CBT and displayed low sustained reactivity to emotional 
stimuli in the subgenual cingulate cortex (Brodmann's area 25) and high activity in the 
amygdala with the strongest improvement. Furthermore, they suggested the presence of 
emotion regulation disruptions, which are targeted in CBT, may be the key to recovery with 
this intervention (Siegle, Carter et al. 2006). Dichter et al. investigated the effects of Behavioral 
Activation Therapy for Depression which was designed and administered to increase 
engagement with positive stimuli and a reduction in avoidance behaviors. A high responder rate 
of 75% was reported together with a decreased activation due to cognitive control in prefrontal 
structures including paracingulate gyrus, the right orbital frontal cortex, and the right frontal 
pole. Moreover, the magnitude of the activation in the paracingulate gyrus before treatment was 
related to the magnitude of the change of depressive symptoms after psychotherapy (Dichter, 
Felder et al. 2010). 
Therefore, it can be stated, that there are findings suggesting that also psychotherapeutic 
treatment affects processing of emotional stimuli with changes in the activity of the amygdala 
and other brain regions, which even may be interrelated to the effectiveness of the treatment. 
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1.4. The processing of facial expressions 
Facial expressions are an important component of communication and the correct interpretation 
of emotional expression is an essential key of successful social relationship. There are some 
studies suggesting that difficulties in interpersonal communication in depressed patients may 
be related to abnormalities in affective facial processing (Fu, Williams et al. 2004). There have 
been published several studies investigating facial emotional processing in depressed patients. 
Some of them are focused on facial expressions because this may facilitate a better 
understanding of facial emotion processing due to impaired cognition regarding to different 
neural regions within the central nervous system (CNS). In addition, impaired facial expression 
processing may link to other affective and social symptoms in depressed patients. Finally, a 
change in facial emotional processing during response to antidepressant treatments may help to 
predict this treatment response in depressed patients (Venn, Watson et al. 2006). Therefore, 
presenting facial emotional expression stimuli may be a valid and reliable approach for emotion 
processing investigations in order to activate brain areas responsible for emotion processing in 
healthy volunteers and in MDD patients with impaired cognition (Fusar-Poli, Placentino et al. 
2009). 
Ekman and Friesen (1971) suggested that six basic emotional expressions could be recognized. 
The investigated basic emotional expressions were shown in happy, sad, fearful, angry, 
disgusted, and surprised faces. In addition, they developed a standardized set of stimuli on the 
basis of these six emotions which were widely used in behavioral, cognitive and neuroimaging 
investigations (Ekman and Friesen 1971). Since then imaging studies in affective cognition 
often used Ekman stimuli for the measurement of responses to emotional faces. 
1.5. Influence of Major Depression on processing of facial expressions 
According to the cognitive theories of depression, symptoms coming from mood-congruent 
emotions cause a processing bias. Consequently, patients suffering from MDD tend to attend 
more to negative emotional stimuli (Scher, Ingram et al. 2005, Beck 2008). Several studies are 
reporting a negative bias on the perception of social key signals such as emotional facial 
expressions. This was demonstrated also in cognitive and behavioral investigations (Gur, Erwin 
et al. 1992, Bouhuys, Geerts et al. 1999). In addition, neuropsychologic studies have reported 
that MDD patients have a significant bias toward sad emotions (Gotlib, Krasnoperova et al. 
2004). Another study has shown that MDD patients interpret happy facial expressions as neutral 
and neutral facial expressions as sad emotions (Persad and Polivy 1993). Such biases have been 
associated with aberrant responses across a network of neural areas involved in emotional 
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processing, including an increase in the response of the amygdala to negative facial expressions 
in depressed patients compared to matched controls (Sheline, Barch et al. 2001, Surguladze, 
Young et al. 2004, Suslow, Konrad et al. 2010, Victor, Furey et al. 2010). 
1.6. Magnetic resonance imaging and functional MRI 
Magnetic resonance imaging (MRI) is a medical imaging technique using strong magnetic 
fields to create images of biological tissue. Functional magnetic resonance imaging (fMRI) uses 
standard MRI scans to investigate changes in brain function over time by determining changes 
in blood flow (Huettel 2014). Blood-oxygen-level dependent (BOLD) contrast is used to detect 
changes in deoxyhemoglobin concentration consequent to task-induced and spontaneous 
modulations of oxygen metabolism in response to neural activity. This method has been widely 
employed in cognition studies for different clinical applications such as surgical planning, for 
monitoring of treatment outcomes, and as a biomarker in pharmacologic and training programs 
(Glover 2011). 
Over the past three decades neuroscientists have tried to clarify the neural mechanisms that 
support face perception (Posamentier and Abdi 2003, Haxby and Ida Gobbini 2007, Fusar-Poli, 
Placentino et al. 2009). Indeed, fMRI studies play a major role in investigations facilitating the 
understanding of human brain function and of neurophysiological substrates of emotional 
processing. Despite the growing number of fMRI studies, some individual imaging studies 
indicate inconclusive findings (Neumann, von Cramon et al. 2008). Predominantly, the 
difficulty to definitively characterize which specific brain region is associated with each 
specific emotional expression has been discussed. Most of the studies employ different imaging 
techniques, analysis methods, and task designs. Nevertheless, fMRI studies showed that 
emotional faces elicit enhanced response in the limbic, frontal, and visual cortical regions 
contrasted to responses evoked by neutral faces (Vuilleumier, Armony et al. 2001, Haxby, 
Hoffman et al. 2002, Winston, O'Doherty et al. 2003, Ishai, Pessoa et al. 2004). 
1.6.1. fMRI and pharmacological MRI 
Pharmacological MRI (phMRI) is a fMRI investigation method to study the effects of 
medication on brain function in response to a chemical substance administration. Bryant and 
Jackson have introduced the application of pharmaco-fMRI for the first time (Bryant and 
Jackson 1998). There are two main approaches in the pharmaco-fMRI field, the first measuring 
acute fMRI signal change following drug administration, while the second estimates 
modulatory effects of a drug on brain networks. (Wandschneider and Koepp 2016). 
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While fMRI is widely used in research and clinical investigation, where it is commonly 
combined with a sensorimotor task, phMRI is an adaptation of fMRI enabling the investigation 
of a specific neurotransmitter system, such as the serotoninergic neurotransmission or the 
melatonin system. These systems are investigated under physiological or pathological 
conditions following an activation via the administration of a specific medication such as 
selective serotonin (5HT) reuptake inhibitors (SSRIs) or melatonin agonists (Klomp, 
Tremoleda et al. 2012). 
1.6.2. Brain regions involved in the processing of facial expression 
Investigations trying to identify brain regions responsible for emotional face processing can be 
subdivided in two major research directions which integrate neuro-anatomical models involved 
in the representation and generation of emotions. These are also thought to influence the 
etiology of MDD (Mayberg 1997, Phillips, Drevets et al. 2003, Phillips, Ladouceur et al. 2008). 
First, encoding of emotional expressions depends on multiple interactions between 
complimentary systems: a neural core system for the visual analysis of faces refers to bilateral 
inferior occipital gyri, the lateral fusiform gyrus and the superior temporal sulcus. The second 
aspect focused on the processing of facial information, such as meaning and significance 
referring to different brain regions such as amygdala, insula, orbitofrontal areas, and 
somatosensory cortex (Haxby, Hoffman et al. 2002). Notably, emotional facial expression 
investigations have been frequently used in neuroimaging studies in depressed patients with 
regards to neurobiological models of depression (Phillips, Drevets et al. 2003, Mayberg 2007, 
Phillips, Ladouceur et al. 2008). 
1.6.2.1. Amygdala 
Functional neuroimaging studies have shown a relevant specific amygdala activation during the 
presentation of fearful facial expressions of emotion (Morris, Frith et al. 1996, Morris, Buchel 
et al. 2001) and during verbally guided anticipation of shock (Phelps, O'Connor et al. 2001). 
This amygdala activation was also reported after brief presentations of fearful facial expressions 
of emotions which were masked to prevent conscious perception (Whalen, Rauch et al. 1998) 
or when presented in the cortically blind field (Morris, DeGelder et al. 2001, Pegna, Khateb et 
al. 2005). There is a large number of functional MRI studies which have shown an increased 
amygdala BOLD response to masked happy or fearful faces (Sheline, Barch et al. 2001). An 
fMRI study detected decreased activity in MDD patients in comparison to healthy controls in 
the left amygdala, during the presentation of sad facial expressions (Fu, Williams et al. 2004). 
 15  
Furthermore, fMRI investigations of affective facial processing of sad and angry faces in 
medicated depressed patients in comparison to healthy controls reported an increased BOLD 
response in the left middle cingulum and the right prefrontal cortex (Frodl, Scheuerecker et al. 
2009). The same study found no differences in amygdala activation between MDD patients and 
healthy controls at baseline before antidepressant treatment (Frodl, Scheuerecker et al. 2011). 
In contrast to these reports, there are a huge number of imaging investigations of facial 
expressions in MDD patients in comparison to healthy controls showing greater amygdala 
BOLD response to emotional facial expressions in MDD (Sheline, Barch et al. 2001, Fu, 
Williams et al. 2004, Lawrence, Williams et al. 2004, Surguladze, Brammer et al. 2005, Fu, 
Williams et al. 2008, Matthews, Strigo et al. 2008, Peluso, Glahn et al. 2009, Suslow, Konrad 
et al. 2010, Victor, Furey et al. 2010, Zhong, Wang et al. 2011). 
1.6.2.2. Hippocampus 
Neuropathology of MDD suggests that an impaired hippocampus may be a key hub within the 
limbic system (Campbell and Macqueen 2004). According to a recent review, hippocampal 
volume reduction is one of the most replicated findings in neuroimaging studies in MDD 
(Roddy, Farrell et al. 2018). For example, reductions in the gray matter volume and functional 
impairment in MDD patients have been reported (Bertolino, Frye et al. 2003, Sheline, Gado et 
al. 2003). Furthermore, some meta-analyses examining MRI studies of the hippocampus, solely 
(Videbech and Ravnkilde 2004, McKinnon, Yucel et al. 2009, Cole, Costafreda et al. 2011) or 
as part of a greater limbic system analysis (Koolschijn, van Haren et al. 2009, Kempton, 
Salvador et al. 2011, Arnone, McIntosh et al. 2012), have found volume reductions of 4% to 
10% in depressed patients. Although some imaging studies in depression observed activations 
in parts of the amygdala extended to (para)hippocampal regions in response to emotional facial 
expression, patients suffering from MDD showed predominantly an elevated amygdala-
hippocampal BOLD response to sad conditions when compared to healthy individuals (Fu, 
Williams et al. 2008). There are not many studies in depressed patients demonstrating a 
decreased BOLD response to sad facial expression directly in the hippocampus (Lee, Seok et 
al. 2008). In contrast, a study by Videbech et al. reported that MDD patients showed increased 
activity of the hippocampus and the cerebellum relative to the healthy controls (Videbech and 
Ravnkilde 2004). 
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1.6.2.3. Insula 
Fusar-Poli et al. performed a metanalysis of 105 fMRI studies on healthy subjects and reported 
the processing of facial expressions (emotional and neutral) is associated with an elevated 
activation in temporoparietal areas, such as the parietal lobe, the middle temporal gyrus and the 
insula. That was specifically true for the contrast of neutral facial expressions versus baseline 
in the left insula, the processing of happy facial expressions versus baseline in the left insula, 
of sad facial expressions versus baseline in the left insula, and of disgusted facial expressions 
compared with baseline in the right insula (Fusar-Poli, Placentino et al. 2009). 
According to a review by Stuhrmann (Stuhrmann, Suslow et al. 2011), an imaging study by 
Surguladze et al. investigated the BOLD response to faces displaying different degrees of 
disgust in MDD patients in contrast to a healthy control group. They identified greater left insula 
activation in the depressed patients in comparison to the group of healthy controls (Surguladze, 
El-Hage et al. 2010). Irrespective of an altered processing of disgust in major depressed 
patients, also an altered activation in the insula to other emotional facial expressions has been 
published (Suslow, Konrad et al. 2010). Zhong et al. demonstrated a greater activation in the 
insula and the parahippocampal gyrus (PHG) to sad facial expression and a decreased activation 
to happy facial expression (Zhong, Wang et al. 2011). Fu et al. have shown an increased insula 
activation to fearful/angry (combined contrast) facial expressions in a sample of young MDD 
patients (Fu, Williams et al. 2004). Notably, they could demonstrate a thalamic hyper-
responsiveness to sad facial expressions. 
Currently in most of the reviewed imaging studies on processing of emotional facial expression 
there is a clear trend for similar activation patterns between the insula, the parahippocampal 
gyrus area and the amygdala, demonstrating an emotional bias of the activity in limbic 
structures in MDD patients in contrast to healthy individuals. This includes a greater BOLD 
response to negative facial expressions and an increased BOLD response to happy facial 
expressions. One study reported also a different pattern of decreased activity in the insula in a 
combined contrast of sad and fear facial expressions in MDD patients (Townsend, Eberhart et 
al. 2010). 
Some studies identified aberrant activity in striatal structures which also had similar activation 
patterns like that reported in the amygdala and insula. It was demonstrated that predominantly 
the putamen and caudate nucleus show a greater BOLD response to sad/angry facial expressions 
 17  
and increased BOLD response to happy facial expressions (Fu, Williams et al. 2004, Lawrence, 
Williams et al. 2004, Fu, Williams et al. 2008, Scheuerecker, Meisenzahl et al. 2010). 
1.6.2.4. Motor cortex and prefrontal cortex 
The role of the prefrontal cortex (PFC) in facial emotional processing in depression so far is 
less clear (Stuhrmann, Suslow et al. 2011). Using different imaging methods such as positron 
emission tomography (PET), neuroscientists have focused on the PFC and specially on the 
dorsolateral prefrontal cortex (DLPFC) function in MMD patients. There are studies reporting 
a reduced cerebral blood flow and metabolism in the left DLPFC and hypermetabolism in the 
right DLPFC in acute MDD (Mayberg 2003, Phillips, Drevets et al. 2003, Grimm, Beck et al. 
2008). 
Mayberg’s limbic-cortical dysregulation model based on evidence from a series of PET studies 
is consistent with the findings of decreased activation in dorsal neocortical regions such as the 
DLPFC and dorsal anterior cingulate cortex (ACC), and of increased activation in paralimbic 
regions such as the insula, amygdala and hippocampus (Mayberg 1997, Mayberg 2003). In the 
lateral PFC no consistent activity pattern in different imaging studies on facial processing in 
MDD in contrast to healthy subjects can be found. Both findings, increased activation and 
decreased activation in the dorsolateral DLPFC in MDD patients to sad and angry facial stimuli, 
can be found nearly equally often (Lawrence, Williams et al. 2004, Keedwell, Andrew et al. 
2005, Frodl, Scheuerecker et al. 2009, Suslow, Konrad et al. 2010, Zhong, Wang et al. 2011). 
Although Davidson et al. reported a hypoactivation of the lateral prefrontal cortex (LPFC) and 
the ACC (Davidson, Irwin et al. 2003), Anand et al. identified the paradoxical imaging study 
results which shows greater activation of prefrontal regions, such as the DLPFC (Anand, Li et 
al. 2005), the medial prefrontal cortex (MPFC) (Anand, Li et al. 2005, Johnstone, van Reekum 
et al. 2007) and the dorsal ACC (Beauregard, Paquette et al. 2006) during the presentation of 
affective stimuli in depressed patients. These reports and their changes after antidepressant 
treatment are summarized and reviewed by Rosenblau et al. (Rosenblau, Sterzer et al. 2012). 
Alterations of neural responses in the MPFC have been reported after successful antidepressant 
combination treatment with the selective noradrenalin and serotonin reuptake inhibitor (SNRI) 
venlafaxine in combination with light therapy (Benedetti, Radaelli et al. 2009). 
Some inconsistencies were reported regarding neural responsiveness to happy facial stimuli in 
the DLPFC and in more ventral, lateral PFC areas. So far, is not possible to draw valid 
conclusions about a general hyper- or hypoactivation of the DLPFC during facial emotion 
 18  
processing in unipolar depression although altered neuronal responses in the DLPFC are a 
prevalent finding in MDD patients due to the high variability in all published neuroimaging 
studies. In the orbitofrontal cortex (OFC) several independent studies detected a decreased 
activation in inferior and medial OFC areas in response to either sad, fearful or angry facial 
stimuli (Lawrence, Williams et al. 2004, Keedwell, Andrew et al. 2005, Lee, Seok et al. 2008). 
Furthermore, Surguladze et al. reported hyperactivation to disgust in the OFC in patients 
suffering from MDD (Surguladze, El-Hage et al. 2010). 
In addition, some facial-processing imaging studies report similar results about activation in the 
prefrontal cortex and the motor cortex. A greater BOLD response to angry facial expressions 
in the motor cortex (Brodmann’s area (BA) 6, BA 4) of MDD patients in contrast to healthy 
controls was shown (Fu, Williams et al. 2004, Keedwell, Andrew et al. 2005, Fu, Williams et 
al. 2008, Scheuerecker, Meisenzahl et al. 2010). 
1.6.2.5. Fusiform gyrus 
In the above mentioned meta-analysis of studies in healthy subjects, the processing of facial 
expressions (emotional and neutral) was associated with an elevated activation in visual areas 
such as the fusiform gyrus. That was reported specifically for the contrast of neutral facial 
expression, fearful facial expressions, and for the processing of disgusted facial expressions 
compared to baseline (Fusar-Poli, Placentino et al. 2009). 
A study by Ho et al. on adolescent MDD patients in contrast to healthy controls identified that 
the fMRI BOLD signal in the left fusiform gyrus during emotional facial processing was 
significantly associated with greater individual-level estimates of perceptual processing 
efficiency. Furthermore, they suggested a facial processing bias in younger MDD patients 
characterized by greater perceptual processing efficiency of emotional visual information in 
sensory brain regions responsible for the early processing of visual information (Ho, Zhang et 
al. 2016). In addition, a study on MDD patient shows increase BOLD response in the fusiform 
gyrus after the presentation of sad facial stimuli (Fu, Williams et al. 2008). 
1.6.2.6. Summary of brain regions involved in the processing of facial 
expression in MDD 
According to the cognitive models of depression and behavioral studies, MMD patients suffer 
from abnormal emotional processing. There are many neuroimaging investigations pointing to 
an emotional processing bias in depressed patients. In addition, reviews of neuroimaging studies 
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have shown that depressed patients have abnormalities within the common face processing 
network, including a mood-congruent processing bias influencing the responsiveness especially 
in the regions amygdala, insula, parahippocampal gyrus (PHG), fusiform face area, and 
putamen. Very often, neuroimaging studies in MDD patients have shown that amygdala 
hyperactivity is associated with negatively biased facial emotion processing. Notably, the 
amygdala, the ACC, OFC, and the DLPFC are core components of a network for emotion 
regulation which is pathologically altered in depressive disorders (Stuhrmann, Suslow et al. 
2011). Furthermore, neuroimaging studies in depression need to extend these findings, 
especially by replicating data with the same activation paradigms and larger sample sizes in 
order to enable researchers to make more valid assumptions on neural emotional processing 
mechanisms before and after administration of antidepressant medications. This may contribute 
to a better understanding of the etiology and mechanisms during effective treatments of 
depressive disorders. 
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1.7. Research questions 
In the following study the evidence for a cognitive neuropsychological model of antidepressant 
drug action has been examined. Using pharmaco-fMRI in a double-blind randomized placebo-
controlled design we investigated the effects of short-term antidepressant treatment in patient 
groups receiving differential treatments. We then compared the BOLD % signal change in the 
defined brain regions of drug treated patients to patients who received placebo treatment. The 
effect of antidepressants (escitalopram, mirtazapine, agomelatine) or placebo on amygdala, 
dorsolateral prefrontal cortex, fusiform gyrus, hippocampus and insula (all bilateral) was 
investigated. BOLD responses to facial expressions in patients with MDD were investigated. 
In addition, the HPA axis activity of a subgroup of patients was studied before treatment and 
after one week of acute treatment to elucidate the relationship between amygdala response 
during facial processing and HPA-axis hyperactivity in relation to the clinical outcome before 
and after short-term treatment. 
The following research questions should be answered with our study: 
1) Is the fMRI BOLD % signal change during facial processing of MDD patients in several 
regions of interest (ROIs: amygdala, DLPFC, hippocampus, insula, and fusiform gyrus) 
influenced by a short-term antidepressant treatment? 
2) Are there detectable differences of the BOLD response to facial processing between the 
drug-treated (escitalopram, mirtazapine, or agomelatine) patients and and the placebo-
treated patients after one week of short-term treatment? 
3) Are there detectable differences of the BOLD response to facial processing between the 
four different treatment groups (antidepressants escitalopram, mirtazapine, agomelatine 
or placebo) after one week of active or placebo treatment? 
4) Is there a detectable correlative relationship between clinical outcome (measured using 
the Hamilton rating scale for depression) and the BOLD % signal change in different 
ROIs during facial processing before and after one week of treatment with the 
antidepressants escitalopram, mirtazapine or agomelatine, versus placebo? 
5) Is there a correlative relationship between the HPA-axis (hyper)activity in MDD and 
the BOLD % signal change during facial processing? Is this putative correlation altered 
after one week of antidepressant-drug treatment? 
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2. Methods 
2.1. Study design 
This study is part of the project “Relevance of the gut-microbiome composition für subtypes of 
depression, response and side effects during antidepressant treatment“ which is a part of the 
German reseach network “Novel strategies for the optimized treatment of depression 
(OptiMD)” funded by the Federal Ministry of Education and Research (Bundesministerium für 
Bildung und Forschung, BMBF, www.bmbf.de, support code 01EE1401B). 
The single center study was carried out as a randomized, double-blind and placebo-controlled 
trial in a parallel group design. Ethical approval was granted by the local Ethics committee of 
the University Regensburg. The clinical trial was registered and approved by the Federal 
Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, 
BfArM, www.bfarm.de). 
2.1.1. Study sample and patient selection 
All patients were included in the study after adequate explanation of the study procedures and 
after they provided written informed consent. They were investigated at the Department of 
Psychiatry and Psychotherapy of the University Regensburg, located in the Bezirksklinikum 
Regensburg, Universitätsstraße 84 in 93053 Regensburg, Germany. We included 33 major 
depressed in-patients admitted for the treatment of a major depressive disorder independently 
of study participation. Patients were not treated with antidepressants or other psychotropic 
substances except lorazepam for agitation or zopiclone for insomnia during the first pre-
treatment fMRI and during the first combined Dex/CRH-test. Table 2 shows clinical and 
demographic data for the patients. In all participants we assessed the presence of current and 
past psychiatric disorders using the Mini-International Neuropsychiatric Interview (M.I.N.I.) 
(Sheehan, Lecrubier et al. 1998) for the 10th version of the International Classification of 
Diseases (WHO 2016). The depressed patients met criteria for a primary diagnosis of major 
depressive disorder (MDD) and were not suffering from other psychiatric diagnoses. In addition 
they were physically healthy and not suffering from serious somatic diseases. Medical history, 
psychiatric history, vital signs, a laboratory screening and an electrocardiogram (ECG) were 
assessed. The principles of informed consent were implemented according to the current 
revision of the Declaration of Helsinki, the International Council for Harmonisation of 
Technical Requirements for Pharmaceuticals for Human Use (ICH) Guideline for Good 
Clinical Practice and regulatory requirements. All patients are included in the study after 
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adequate explanation of the study procedure and after written informed consent. Withdrawal of 
consent was possible at any time during the study. 
Our detailed study inclusion criteria were: 
 Male and female in-patients in the age between 18 and 65 years; 
 Major depressive disorder; 
 Admission on a voluntary basis independent of our study; 
 Written informed consent for trial participation after the scope and nature of the 
investigation have been explained to the patients before starting trial-related activities; 
 Indication for antidepressant therapy independent of the clinical trial; 
 Primary unipolar depression (ICD-10: F32, F33) or bipolar depression (ICD-10: F31.3-
5), current episode of depressed state for at least 2 weeks prior to baseline; 
 Physically healthy; 
 Right handedness (assessed by the Edinburgh Handedness Inventory (Oldfield, 1971)). 
The detailed exclusion criteria were: 
 Schizophrenia, substance dependence as define by ICD-10 or any other psychiatric 
primary diagnosis (according to the ICD-10 criteria); 
 major somatic or neurological disorder; 
 abnormalities in the laboratory screening at baseline (e.g. hypo- or hyperthyroid state, 
hyperhidrosis, elevated liver enzymes, blood cell dyscrasias); 
 lacking ability to give informed consent; 
 have been admitted to the clinic involuntarily during their present episode; 
 pregnancy or breast-feeding; 
 in case of the inclusion of premenopausal female patients insufficient contraception 
leads to exclusion from the study; 
 contraindications to magnetic resonance imaging patient with heart pacemaker or 
implanted metal in the scull; 
 or concurrent medication, which could alter emotional processing; 
 known history of alcohol or drug abuse during 6 month prior to the screening; 
 being at clinically risk of suicidal behavior (HAM-D Item 3 > 2 or clinical impression); 
 involuntary admission to the hospital; 
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 known allergies or hypersensitivity reactions or other contraindications for 
escitalopram, agomelatine or mirtazapine; 
 being treated with psychotropic medication < 3 weeks before study (5 weeks in case of 
fluoxetine pretreatment); 
 Unusual diets leading to malnutrition; 
 Pretreatment with antibiotics or corticosteroids. 
Discontinuation criteria were: 
 Withdrawal of consent at any time during the study period; 
 If necessary concerning clinical reasons, investigators and sub-investigators could stop 
the study participation of an individual patient; 
 Noncompliance to the study protocol. 
Our goal was to provide a better understanding of the interactions between neural systems 
during antidepressant treatment, the effect of antidepressants on emotional processing, the 
relationship between amygdala hyperactivity as well as other brain regions BOLD response to 
emotional facial expression, and the HPA axis activity in relation to clinical effectiveness of 
the treatment measured using the 21-item version of the Hamilton Rating Scale for depression 
(HAM-D21) (Hamilton 1967). 
In this study firstly, we considered the evidence for a cognitive neuropsychological model of 
antidepressant drug action. We used pharmaco-fMRI (3T) to investigate the effect 
antidepressant treatment on the amygdala (right (R)+left (L)), caudate (R+L), dorsal lateral pre-
frontal cortex (DLPFC) (R+L), fusiform gyrus (R+L), hippocampus (R+L) and insula (R+L) 
BOLD response to facial expression at baseline and after one week of antidepressant treatment 
(antidepressants or placebo in addition to psychotherapy) in major depressed patients. 
Secondly, we investigated the activity of the hypothalamus-pituitary-adrenal (HPA)-axis using 
the combined dexamethasone suppression / corticotropin releasing hormone (Dex/CRH) 
stimulation test before and after one week of treatment to elucidate the relationship between 
BOLD response signal change and HPA-axis activity. 
Thirdly, we clinically assessed the patients before, during and after treatment periods using the 
HAM-D21 (Hamilton 1967) rating scale as the primary outcome criterion. 
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2.1.2. Study design and drug treatment  
Double-blind, placebo-controlled, parallel group study in 33 depressed patients who were 
randomly assigned to 4 groups. The patients in each group received either 10 mg Escitalopram, 
30 mg Mirtazapine, 25 mg Agomelatine or placebo for at least 7 days. The patients receive the 
medication at 8:00 am in case of escitalopram or at 10:00 pm in case of agomelatine and 
mirtazapine treatment according to usual clinical procedures. For blinding a double-dummy 
technique was used. On study day 4 and 11, i.e. the days of pharmaco-fMRI scans, the patients 
received the medication in the morning at 8:00 am (about 4 hours before the fMRI scan). All 
four groups then received the fMRI scan before treatment and after the seventh day of the 
treatment. In addition, on the 2nd and 9th day of the study we investigated the levels of cortisol 
secretion by using combined Dexamethasone suppression / corticotropine-stimulation 
(combined Dex/CRH-) tests. Mood and anxiety were assessed primarily using the HAMD-21 
scale by trained psychiatrists immediately before starting treatment, on the 7th day of 
escitalopram, mirtazapine, agomelatine or placebo treatment and then in weekly intervals until 
discharge of the hospital. After the second fMRI scan in case of partial response (defined as at 
least 10% reduction in HAMD-21 scale) treatment was continued without change, in case of 
nonresponse a dose increase or change of the treatment was offered to the patients. The same 
was true if no reduction of at least 20% was seen after 2 weeks of treatment according usual 
clinical procedures. On the day of inclusion a laboratory screening and on the days of the fMRI 
scan blood withdrawals for the estimation of drug plasma levels of the used antidepressants 
were performed. The measurement of plasma levels was performed after unblinding the 
medication. For the study flow chart see Table 1. 
In case of clinical necessity a concomitand treatment with hypnotics, including lorazepam (up 
to 3 mg/d), zopiclone (up to 15 mg/d) or zolpidem (up to 20 mg/d) was allowed. On the days 
before and the days of the pharmaco fMRI scan and the Dex/CRH-test concomitant medication 
was avoided. After study participation all patients received further treatment according to 
clinical indications. Each patient advised independently of the study only according to clinical 
reasons. In case patients responded well to the treatment, it was considered to continue 
pharmacotherapy. In case of nonresponse other pharmacological and non-pharmacological 
interventions including augmentation strategies were offered. 
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Table 1: Study flow chart and investigation plan for the blinded short-term treatment period  
(MED = medication) 
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2.1.3. Functional magnetic resonance imaging data acquisition  
fMRI data collection was done using three different 3 Tesla (3T) scanners due to a replacement 
of the research scanner of the University Regensburg. From the total of 33 patients, 2 were 
investigated using a Siemens MAGNETOM Allegra head scanner for 3T brain imaging 
(Siemens AG, Erlangen, Germany), fitted with a birdcage headcoil, which was located at the 
department of neuroradiology of the University Regensburg, Center for Clinical Magnetic 
Resonance Research. Eight of the patients were investigated using a Siemens MAGNETOM 
Skyra full-body scanner for 3T imaging, located at the Institute of Radiodiagnostics at the 
University Hospital Regensburg, and 23 of the patients were scanned using a Siemens 
MAGNETOM Prisma head scanner for 3T brain imaging with the 20-channel headcoil, located 
at the Bezirksklinikum Regensburg (clinical center of the district Upper Palatinate), Center for 
Clinical Magnetic Resonance Research. The study participants completed a neuroimaging 
battery including high-resolution structural, resting state, and functional task scans. Only the 
data from the facial emotion processing task described in the following was used for the current 
analysis. 
2.1.4. Functional MRI experimental task 
Before each fMRI task investigation all patients were screened and asked to disclose any 
ferromagnetic implants and devices such as cardiac pace makers, before they entered the MRT 
scanner completely metal free. During the fMRI scanning, participants were asked to process 
visual stimuli and complete a simple gender discrimination task, involving the rapid 
presentation of emotional and neutral facial expressions or scrambled pictures. In this task, they 
viewed male and female emotional faces. As a starting basis the Averaged Karolinska Directed 
Emotional Faces (AKDEF) were used. This is a set of totally 70 pictures of averaged human 
facial expressions. The material was developed in 1998 by Daniel Lundqvist and Jan-Eric Litton 
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at Karolinska Institutet, Department of Clinical Neuroscience, Section of Psychology, 
Stockholm, Sweden (Lundqvist D 1998). All faces were modified from the original pictures of 
the KDEF set to provide a similar proportion and distribution of light and dark areas to prevent 
confounding effects independent from facial expressions. Therefore, we masked all pictures to 
cover parts of the hair and to present identical black and white pictures to keep the attention 
only on facial expression. The patients were asked to report the gender of the face via an MRI 
compatible keypad. Stimuli were presented on a computer using A simple framework (ASF) for 
behavioral and neuroimaging experiments (Schwarzbach 2011) based on the psychophysics 
toolbox (Brainard 1997) for the MATLAB software package (MATLAB_R2016b, 
Adalperostraße 45, 85737 Ismaning, Germany, 
https://de.mathworks.com/products/matlab.html) and on a cloned projection display to patients 
on an opaque screen located at the head of the scanner bore, which subjects view using angled 
mirrors. Subject responses were registered via an MRI-compatible keypad. Immediately before 
scanning, all subjects received training with another set of stimuli to ensure that they fully 
understood the requirements of the task. 
There were 18 blocks of the emotional task that contained 10 images (for a given condition), 
and each image was presented for 1.6 seconds (s). The task had seventeen 16s blocks of a 
baseline fixation point, an interleave with eighteen 16s blocks of the facial or scrambled task 
blocks of afraid, angry, happy, neutral, and sad faces, and of scrambled pictures (figure 1). 
There was no masking between the images. They were merely presented back-to-back within a 
block. Each condition was repeated 3 times per run (i.e., 6 conditions [afraid, angry, happy, 
neutral, sad, scrambled]*3 repetitions = 18). Each run was repeated 3 times in a given session 
(i.e., pre or post). 
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Figure 1: Presented emotional faces during the scan time. The task was to press a button corresponding to the 
recognized gender in facial pictures or the localization of dark areas in scrambled pictures. 
During each emotional block, participants viewed 10 emotional faces (male and female). Each 
face was presented for 1.6 s and subjects were asked to report the gender of the face via a MRI 
compatible keypad to ensure patients remaining on focus during the task. They were instructed 
to press one key with the index finger when they recognized a female face and another key with 
the middle finger when they recognized a male face. In case the scrambled pictures were 
presented, they should press one key with their index finger when a picture with more darkness 
at the bottom was shown and another key with their middle finger in case darker areas are 
located in the upper parts of the pictures. The patients were asked to lie calmly without moving 
their head. The total duration of the fMRI procedure was about 60 minutes per session. Each 
session consisted of 30 min facial task, the results of which are presented here. This was 
combined with 20 min resting state and 12 min diffusion tensor imaging (DTI) sequences which 
have been analyzed in another subproject. 
2.1.5. Dex/CRH Test  
To investigate the activity of the HPA axis, two Dex/CRH-tests in each patient were performed. 
The first test was performed before treatment on days 1 and 2, the second after the short-term 
treatment of one week on day 8 and 9. 
The patients received 1.5mg Dexamethasone (Dex) (Fortecortin®, Merck KG, Darmstadt, 
Germany) orally at 11:00 pm on the day 1 (first day of the test) before the CRH challenge 
(second day of the test). On the day of the CRH stimulation test at 2:30 pm an intravenous 
forearm catheter was inserted and the first blood samples were collected. The patients had to 
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stay supine on a bed in a single room under resting conditions. After a 30min adaptation period 
baseline probes were acquired. At 3:00 pm a bolus of 100μg human CRH lyophilisate (CRF 
human, Clinalfa® AG, Läufelfingen, Switzerland) was injected within 30s. Blood samples were 
collected at 3:00, 3:30, 4:00 and 4:15 pm. Blood sampling and CRH injection were performed 
using the “through-the wall”-technique to avoid disturbance of the patients. 
Serum for cortisol determination was stored frozen at –80 °C until en bloc assessment. Cortisol 
was quantified in 20μl plasma using a commercial enzyme linked immunosorbent assay 
(ELISA) (Cortisol-ELISA RE52061, IBL international, Flughafenstraße 52a, D-22335 
Hamburg, Germany). The detection range is 20-800 ng/mL. 
2.1.6. Clinical assessment and psychiatric ratings 
The HAM-D sum score was assessed after an interview of trained psychiatrists. The HAM-D21 
scale consists of 21 single items related to depression. Their severity was determined in a semi-
structured interview. The items were depressed mood, feelings of guilt, suicide, insomnia - 
early, insomnia - middle, insomnia - late, work and activities, retardation, anxiety - psychic, 
anxiety - somatic, somatic symptoms – gastrointestinal, somatic symptoms – general, genital 
symptoms, hypochondriasis, loss of weight, insight, diurnal variation, depersonalization and 
derealization, paranoid symptoms, and obsessional and compulsive symptoms. 
2.1.7. Statistical analyses 
2.1.7.1. Demographic and clinical variables 
Statistical analyses included descriptive variables (mean, standard deviation, and standard 
error), the Kolmogorov-Smirnov testing for normal distribution, non- parametric and 
parametric (if applicable) comparisons of the mean, comparisons of frequencies in the treatment 
groups (crosstabs, 2-tests, Fisher ś exact-tests). Comparisons of the mean of more than two 
groups are performed using an univariate analysis of variance (ANOVA) with post-hoc 
comparisons of means (corrected for multiple testing). Cortisol secretion profiles are compared 
between different groups using the repeated-measurement ANOVA. Statistics were calculated 
using the software IBM SPSS Statistics Version 24 (https://www.ibm.com/products/spss-
statistics). 
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2.1.7.2. fMRI data analysis 
2.1.7.2.1. Preprocessing 
For the preprocessing of all images the software package Statistical Parametric Mapping 
SPM12 (Wellcome Centre for Human Neuroimaging, http://www.fil.ion.ucl.ac.uk/spm/) and 
the MATLAB software package were used. For each individual patient the functional images 
were slice-time corrected to time repetition (TR) divided by 2 (TR/2). This funcion corrects 
differences in slice acquisition times and is an important step in fMRI preprocessing (Parker, 
Liu et al. 2017). The next step proceeded with the Realignment Estimate and Reslicing. This 
means, each individual imaging dataset was realigned to the first volume by rigid body 
transformation to correct for head motions of the participants. Ashburner and Friston noted that 
the aim of this realignment is to remove movement artefact in fMRI or PET times- series 
(Ashburner J 1997). In a third step, before performing the coregistration and normalization steps 
in SPM, all individual structural images were reset to their origin in the anterior commissure 
(AC). The next step was to proceed with coregistration and estimation of each patient´s 
structural image. In general, proceeding with the registration based on the work of Collignon et 
al. who recommended the coregistration of structural images to the mean of realigned functional 
images using a 12-parameter affine transformation (Collignon A 1995). The “reference image” 
is the image supposed to remain static while the structural source image is moved to match it. 
Furthermore, the structural images were segmented according to the standard procedure in 
SPM12 (Ashburner and Friston 2005). Then the spatial normalization to the standard Montreal 
Neurological Institute (MNI) space) was applied to the functional images to allow for 
intrasubject analysis. Then spatial smoothing using an 8 mm Gaussian kernel full width at half 
maximum was applied to increase the signal-to-noise ratio. The reason using smoothing in 
preprosseing steps was is suppress noise and effects due to residual differences in functional 
and gyral anatomy during inter-subject averaging. All procedures were performed with 
consideration of the SPM12 manual (Ashburner 2018). 
2.1.7.2.2. Statistical analysis of the images - First level (individual) 
analysis 
All statistical first and second-level analyses were conducted with SPM12 for each individual 
patient based on the general linear model (GLM). Six types of events were distinguished: afraid, 
angry, happy, sad, and neutral facial expressions, and scrambled pictures, which were repeated 
in 3 runs of two scanning sessions. In the event design, a general linear model was then applied 
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to the time course of activation in which stimulus onsets were modelled as single impulse 
response functions and then convolved with the canonical hemodynamic response function 
(HRF) (Friston, Worsley et al. 1994). The data were high-pass filtered with a frequency cutoff 
at 128 seconds. Statistical parametric maps (SPMs) were generated for each subject by t-
statistics derived from contrasts utilizing the HRF (Friston, Penny et al. 2002). After that model 
parameters estimated using classical (ReML - Restricted Maximum Likelihood) or Bayesian 
algorithms. 
2.1.7.2.3. Contrasts computed on the individual analysis level 
The following contrasts of interest were computed on the individual analysis level, while the 
the comparison of each emotional face condition with neutral facial expressions or scrambled 
picture conditions or with baseline were the main focus. Therefore, 19 t-test contrasts were 
calculated comparing neutral faces or scrambled pictures with emotional facial conditions. In 
addition, the different emotions were compared with each other. Therefore, a set of nineteen 
subsequent contrasts was acquired for each individual subject: 
1) afraid > neutral 
2) afraid > scrambled 
3) angry > neutral 
4) angry > scrambled 
5) happy > neutral 
6) happy > scrambled 
7) neutral > scrambled 
8) sad > neutral 
9) sad > scrambled 
10) afraid > happy 
11) angry > happy 
12) sad > happy 
13) all facial expressions > scrambled 
14) afraid > baseline 
15) angry > baseline 
16) happy > baseline 
17) neutral > baseline 
18) sad > baseline 
19) scrambled > baseline. 
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2.1.7.2.4. Group analysis 
To assess differences in BOLD response to facial expressions or scrambled pictures in different 
stages of treatment (before and after one week of active treatment) or in different medication 
groups (one of the three antidepressants or placebo), all groups results were subdivided with 
regard to our three main questions: 
20) All patients pre-post comparison: To access % signal change differences before and 
after short-term treatment, we assessed all patients together, divided to two sessions (the 
pre-treatment session compared to the post-treatment session); 
21) Post-treatment sessions: The group of all medicated patients together (agomelatine, 
mirtazapine, escitalopram groups pooled) compared to the placebo group; 
22) Post-treatment sessions: The pairwise comparisons of four treatment groups 
(agomelatine, mirtazapine, escitalopram and placebo). 
In the group analysis regarding the three different questions all the groups engaged the same 
step of group analysis procedure after defining the contrast and model estimation. 
2.1.7.2.5. Second level analysis 
These single-subject first-level contrast images from the weighted beta-images were engaged 
into a second-level random-effects analysis to start the group analysis. For each contrast a one-
sample t-test was conducted. All fMRI results reported here are subdivided to two different 
group analysis views. The first reported results are based on voxel statistics computed with 
SPM for the whole-brain exploratory analysis. The resulting set of significant voxel values for 
each contrast constituted an SPM map. The maps were thresholded at T = T = 5.45 [p < 0.05 
(Family-Wise Error, FWE)] and overlaid on the MNI template, and labelled according to MNI 
coordinates. For graphical purposes in those brain regions showing significant effects mean 
cluster values (parameter estimates) were extracted by using the SPM12 software. The other 
group analysis results reported here were computed with ROI analysis, based on 10 regions of 
interest. 
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2.1.7.2.6. Region of Interest (ROIs) analysis 
Defining of region of interest: According to our hypotheses we choose 10 regions of interest as 
follows (ROI, coordinates; radius of ROI = 5 mm): 
23) Left amygdala (-23.5, -1.95, -18.5) 
24) Right amygdala (27.1, -0.573, -18) 
25) Left hippocampus (-25.3, -22, -11.4) 
26) Right hippocampus (28.9, -21, -11.6) 
27) Left insula (-35.4, 5.44, 2.17) 
28) Right insula (38.7, 5.02, 0.814) 
29) Left fusiform gyrus (-31.4, -41.4, -21.6) 
30) Right fusiform gyrus (33.7, -40.2, -21.5) 
31) Left dorsolateral prefrontal cortex (DLPFC) (−46, 38, 12) 
32) Right DLPFC (46, 38, 12) 
The ROIs no. 1 to 8 were selected using the standard automated anatomical labelling (AAL) 
procedure for structural ROIs described more in detail in Tzourio-Mazoyer et al. (Tzourio-
Mazoyer, Landeau et al. 2002). The ROI contains ROIs in the format of the MarsBaR region 
of interest toolbox for SPM (Brett M 2002). ROIs 9 and 10 were selected using the Montreal 
Neurological Institute (MNI) coordinates of the regions of interests in the default mode network 
(DMN) and in the executive control network (De Pisapia, Bacci et al. 2016). 
2.1.7.2.7. The MarsBaR / SPM interface 
The ROI analysis was done with the SPM toolbox MarsBaR (Brett M 2002) using the following 
procedure: First, the ROI was characterized by defining the center of the mass (ROI 
coordinates) and defining a 5 mm radius sphere around the center. Then, the % signal change 
was produced from computed results of the 1st level of the analysis for each session of each 
individual patient and 19 differential contrasts in all ROIs separately. 
Finally, differential mean values were calculated and compared. For the comparison of the % 
signal change for each group and ROI before and after antidepressant treatment (pre / post 
comparison) using SPSS the repeated measures analysis of variance (rmANOVA) was utilized. 
For the comparison of the treatment groups described on page 31 an univariate ANOVA was 
performed. 
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2.1.7.2.8. Final statistical evaluation 
To evaluate significant time effects on the BOLD % signal change before and after one week 
of antidepressant short-term treatment an ANOVA for repeated measurements (rmANOVA) 
with time as within-subjects factor was performed. After using contrasts between different 
conditions (all facial and scrambled pictures) in all regions of interest (ROIs) predefined 
according to our hypotheses, differential contrasts between different emotional and neutral 
faces and scrambled pictures were computed. All analyses were first done for baseline values 
of the BOLD % signal change in the group of all patients together. Then different treatment 
regimes were compared by rmANOVA with group as a between subjects factor. Different 
therapeutic conditions were summarized first: the group of patients receiving antidepressant 
medications agomelatine, escitalopram or mirtazapine were compared to the placebo treated 
patients. In a final step each treatment group (agomelatine, escitalopram, mirtazapine and 
placebo) were analyzed separately. Furthermore, correlative analyses with the BOLD % signal 
change of all contrasts to baseline and all contrasts between emotional conditions and scrambled 
pictures were performed. For that purpose, areas under the curve (AUC) for cortisol 
concentrations vs. time were calculated by numerical integration using the trapezoidal rule. 
Then, correlations were calculated for fMRI data and clinical variables (HAM-D21 sum scores) 
and for fMRI data and the HPA-axis activity (cortisol areas under the curve (AUC), baseline 
corrected AUCs and peak values). Since some of the variables were not normally distributed, 
the nonparametric Spearman correlation coefficient was calculated. In addition, the Pearson 
correlation coefficient was used after clarifying the normal distribution of each used variable 
with the Kolmororov-Smirnov test. 
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3. Results 
To reject or confirm our hypotheses and to answer the main questions of the three experiments, 
first the demographic variables are displayed to characterize the investigated sample of 33 
major depressed patients investigated before and after one week of antidepressant treatment. 
The first experiment is subdivided in two main parts: In the first part, in a pharmaco-fMRI study 
the BOLD % signal changes before and after treatment during the presentation of emotional 
facial expressions (afraid, angry, happy, sad, neutral) or scrambled pictures in predefined 
regions of interest (ROI analysis) were compared. These results represent the main findings of 
the present study. In the second part, the peak voxel activation was assessed in an exploratory 
study part using a whole brain analysis. 
The second experiment was designed to clarify the effects of antidepressants and placebo on 
different brain regions of interest. Therefore, the results are subdivided into two sections. In the 
first part, the BOLD % signal changes between medicated patients and placebo treated patients 
were compared. In the second part, effects of three different antidepressants or placebo on the 
BOLD % signal changes in the same predefined ROIs were investigated. 
Finally. in the third experiment, interdependencies between the BOLD % signal change in the 
ROIs and the clinical outcome measured with the HAM-D21 scale and the HPA-axis activity 
considering cortisol secretion during both combined Dex/CRH-tests were investigated in 
correlative analyses. 
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3.1. Demographic and clinical variables 
We investigated a total of 33 patients suffering from MDD who were randomized to four 
treatment goups. Their mean age was 32.6 ± 12 years (mean ± standard deviation, STD). 
Differences in their mean age in the treatment groups were not statistically significant (ANOVA 
F [3, 32] = 1.96, p > 0.05). Nor was the sex distribution significantly different in the treatment 
groups (2 [3, 32] = 2.63, p > 0.05) (table 2). 
Table 2: Demographic data and clinical variables. 
 
n age 
± SEM 
sex 
(m/f) 
HAM-
D21  
day 1 
± SEM 
HAM-
D21  
day 11 
± SEM 
HAM-D21  
discharge 
± SEM 
placebo 9 25.9 ± 
1.6 
5 / 4 24.8 ± 
1.8 
18.3 ± 
1.7 
(13.4 ± 2.3) 
agomelatine 7 38.4 ± 
6.7 
5 / 2 27.7 ± 
1.8 
21.3 ± 
1.6 
17.6 ± 2.5 
escitalopram 9 31.3 ± 
3.2 
8 / 1 25.9 ± 
1.6 
19.7 ± 
1.9 
12.7 ± 1.5 
mirtazapine 8 36.4 ± 
4.1 
5 / 3 27.3 ± 
1.7 
21.1 ± 
1.3 
15.1 ± 1.9 
total 33 32.6 ± 
2.1 
23 / 10 26.3 ± 
0.86 
20.0 ± 
0.83 
14.5 ± 1.0 
P 
(ANOVA, 2) 
33 0.14, 
n.s. 
0.45, 
n.s. 
0.64,  
n.s. 
0.57,  
n.s. 
0.38,  
n.s. 
Our patients showed a significant improvement between the study inclusion before the 1st fMRI 
scan on day 1 and the day of the 2nd fMRI scan (day 11) in the HAM-D21 score (table 2). The 
repeated measurement ANOVA revealed a significant time effect (F [2, 32] = 25.5, P < 0.0001) 
(table 2 and figure 2). 
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Figure 2: Clinical ratings (HAM-D21 scores), all patients summarized before and after the fMRI scans (error 
bars ± standard error of the mean, SEM).  
3.2. Pharmaco-fMRI challenge before and after antidepressant treatment 
3.2.1. BOLD % signal change in different ROIs in all MDD patients before and 
after treatment 
3.2.1.1. BOLD % signal change in the left and right amygdala 
The BOLD % signal change in the left and right amygdala in response to facial expressions 
(afraid, angry, happy, neutral) and scrambled pictures compared to baseline was reduced in the 
fMRI sessions after short-term antidepressant treatment (post session) in comparison to the 
fMRI sesssions before treatment (pre sessions) in MDD patients. There are statistically 
significant differences in the BOLD % signal change between pre and post in the left amygdala 
during the presentation of angry faces versus baseline (rmANOVA: F [1, 32] = 7.01, p = 0.012) 
(figure 3), happy faces versus baseline (rmANOVA: F [1, 32] = 4.23, p = 0.048), and sad faces 
versus baseline (rmANOVA: F [1, 32] = 4.23, p = 0.048). In addition, there are statically 
significant differences between pre and post BOLD % signal change in the right amygdala 
during the presentation of happy faces (rmANOVA: F [1, 32] = 8.08, p = 0.008) and neutral 
faces versus baseline (rmANOVA: F [1, 32] = 4.54, p = 0.042).  
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Figure 3: Statistically significant BOLD % signal change ± SEM after treatment in the left amygdala during 
the presentation of angry (a) and happy (c) faces vs. baseline and in the right amygdala during the 
presentation of happy faces vs. baseline (d). Angry faces vs. baseline in the right amygdala showed 
only a nonsignificant trend (b). 
Furthermore, there are following statistically significant treatment effects in the left amygdala 
of MDD patients during the presentation of sad faces in contrast to neutral faces (rmANOVA: 
F [1, 32] = 7.03, p = 0.012), sad faces in contrast to scrambled pictures (rmANOVA: F [1, 32] 
= 5.10, p = 0.031), angry in contrast to happy faces (rmANOVA: F [1, 32] = 5.96, p = 0.020) 
and all faces versus scrambled pictures (rmANOVA: F [1, 32] = 6.03, p = 0.020). In addition. 
there are significant time effects in the amygdala after one week of antidepressant treatment 
during the presentation of afraid versus neutral faces (rmANOVA: F [1, 32] = 4.19, p = 0.049), 
angry versus neutral faces (rmANOVA: F [1, 32] = 6.41, p=0.016), angry faces versus 
scrambled pictures (rmANOVA: F [1, 32] = 5.18, p = 0.030), happy versus neutral faces 
(rmANOVA: F [1, 32] = 8.12, p = 0.008), happy faces versus scrambled pictures (rmANOVA: 
F [1, 32] = 8.05, p = 0.008), neutral faces versus scrambled pictures (rmANOVA: F [1, 32] = 
4.75, p = 0.037), angry versus happy faces (rmANOVA: F [1, 32] = 5.13, p = 0.030), afraid 
versus neutral faces (rmANOVA: F [1, 32] = 9.63, p = 0.004), sad versus happy faces 
(rmANOVA: F [1, 32] = 7.52, p = 0.010), and all faces versus scrambled pictures (rmANOVA: 
F [1, 32] = 8.27, p = 0.007). 
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Figure 4: Mean BOLD % signal change ± SEM in the amygdala during the presentation of emotional faces. 
Contrasts between different emotions or contrasts between emotions and neutral faces or scrambled 
pictures before and after treatment. 
a) 
b) 
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3.2.1.2. BOLD % signal change in the left and right DLPFC 
The BOLD % signal change in the left dorsolateral prefrontal cortex of MDD patients during 
the presentation of afraid, angry, and neutral facial expressions after one week of antidepressant 
treatment was increased. In the left DLPFC during the presentation of happy or sad faces and 
scrambled pictures in contrast to baseline the BOLD % signal change was reduced. Notably, 
the BOLD % signal change was reduced in the right DLPFC during the presentation to all 
emotional facial expressions and scrambled pictures compared to baseline in the post-treatment 
fMRI sessions. From the described changes, only the BOLD % signal change in the right 
DLPFC was statistically significant reduced during the presentation of angry faces in contrast 
to baseline (rmANOVA: F [1, 32] = 8.65, p = 0.006). 
 
Figure 5: Statistically significant BOLD % signal change ± SEM reduction after treatment in the right DLPFC 
during the presentation of angry faces versus baseline. In the left DLPFC only nonsignificant 
changes could be detected. 
In addition, the following statistically significant treatment effects after short-term 
antidepressant treatment were detected in the left DLPFC during the presentation of afraid vs. 
neutral faces (rmANOVA: F [1, 32] = 17.49, p < 0.001), and in the contrast between all faces 
versus scrambled pictures (rmANOVA: F [1, 32] = 25.39, p < 0.001). Furthermore, there are a 
number of significant time effects in the right DLPFC during the presentation of angry faces in 
contrast to neutral faces (rmANOVA: F [1, 32] = 8.22, p = 0.007), angry faces in contrast to 
scrambled pictures, happy in contrast to neutral faces (rmANOVA: F [1, 32] = 5.59, p = 0.04), 
angry versus happy faces (rmANOVA: F [1, 32] = 4.55, p = 0.041), and sad versus happy (faces 
(rmANOVA: F [1, 32] = 7.12, p = 0.012). 
 40  
Figure 6: Mean BOLD % signal change ± SEM in the left (a) and right (b) DLPFC during the presentation of 
emotional faces. Contrasts between different emotions or contrasts between emotions and neutral 
faces or scrambled pictures before and after treatment. 
a 
b 
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3.2.1.3. BOLD % signal change in the left and right fusiform gyrus 
The BOLD % signal change in the left and right fusiform gyrus of MDD patients during the 
presentation of all facial (afraid, angry, happy, sad and neutral) expressions after short term 
treatment in contrast to baseline was reduced. The reduction was statistically significant in the 
right fusiform gyrus after neutral faces in contrast to baseline (rmANOVA: F [1, 32] = 4.41, p 
< 0.044). 
 
Figure 7: Statistically significant BOLD % signal change reduction after treatment in the right fusiform gyrus 
during the presentation of neutral faces versus baseline. 
Furthermore, there were the following statistically significant time effects after short term 
treatment in the left fusiform gyrus during the presentation of afraid in contrast to neutral faces 
(rmANOVA: F [1, 32] = 35.53, p < 0.001), and all emotional faces in contrast to scrambled 
pictures (rmANOVA: F [1, 32] = 31.97, p < 0.001). 
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Figure 8: Mean BOLD % signal change ± SEM in the right fusiform gyrus during the presentation of 
emotional faces. Contrasts between different emotions or contrasts between emotions and neutral 
faces or scrambled pictures before and after treatment. 
3.2.1.4. BOLD %signal change in the left and right hippocampus 
The BOLD % signal change in post fMRI sessions was increased in the left hippocampus during 
presentation of afraid, angry, and neutral faces and scrambled pictures. The same was true in 
the right hippocampus during the presentation afraid, happy, and sad faces as well as scrambled 
pictures. Furthermore, the % signal change was reduced in the left hippocampus during 
presentation of happy and sad faces. In the right hippocampus % signal change were decreased 
during the presentation of angry and neutral faces (all conditions in contrast to baseline). 
 43  
3.2.1.5. BOLD %signal change in the left and right insula 
The % signal change were reduced in the left and right insula during the presentation of all 
facial (angry, happy and neutral) expression and scrambled picture except afraid compare to 
baseline after short term treatment. 
3.2.2. Peak activation and exploratory whole brain analysis in all MDD patients 
before and after treatment 
Peak activation clusters were revealed by calculating contrasting responses to all faces or 
scrambled pictures versus baseline, all faces versus scrambled pictures, all emotional faces 
versus neutral faces and all negative emotional faces (afraid, angry, and sad) versus happy faces. 
The calculations were done with the fMRI data of the pre-treatment, and the post-treatment 
sessions. 
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Table 3: The peak voxel activation according to the whole brain analysis were exploratorily assed and the 
results were shown in the table below (p < 0.05 with FEW adjustment, the cluster with the global 
maxima were chosen and overlaid on the MNI template, and labelled by using the MNI coordinates 
in SPM12. 
Session 
(group) Condition Volume t-test 
MNI peaks 
X -Y-Z Anatomic region 
pre afraid 1565 13.84 -3, -37, 38 left posterior cingulate gyrus 
(PCgG) 
post afraid 576 13.66 6, -40, 44 right precuneus (PCu) 
pre angry 895 14.21 -9, 38, -4 left anterior cingulate gyrus  
post angry 2077 13.28 -9, -37, 38 left posterior cingulate gyrus  
pre happy 2376 14.40 0, -40, 44 left posterior cingulate gyrus 
(PCgG) 
post happy 3280 12.83 0, -40, 44 left posterior cingulate gyrus 
(PCgG) 
pre neutral 1917 12.54 0, -40, 44 left posterior cingulate gyrus 
(PCgG) 
post neutral 2091 12.09 -6, -40, 41 left posterior cingulate gyrus 
(PCgG) 
pre sad 1868 11.97 0, -40, 44 left posterior cingulate gyrus 
(PCgG) 
post sad 2571 13.20 0, -43, 44 left precuneus (PCu) 
pre scrambled 1232 14.03 0, -61, 26 left precuneus (PCu) 
post scrambled 219 13.23 -51, -70, 26 left angular gyrus (AnG) 
pre afraid > scrambled 2332 12.90 -42, -40, 44 left supramarginal gyrus 
post afraid > scrambled 936 12.59 -33, -46, 44 left superior parietal lobe  
pre angry > scrambled 2113 13.30 45, -34, 44 right supramarginal gyrus 
post angry > scrambled 1101 13.18 -42, -43, 44 left supramarginal gyrus 
pre happy > scrambled 2400 13.63 48, -34, 41 right supramarginal gyrus 
post happy > scrambled 3124 15.00 -39, -43, 41 left supramarginal gyrus 
pre neutral > scrambled 426 14.69 27, 2, 53 right middle frontal gyrus 
post neutral > scrambled 1112 13.74 -33, -46, 44 left superior parietal lobe  
pre sad > scrambled 2062 12.67 48, -34, 44 right supramarginal gyrus 
post sad > scrambled 2875 13.83 -24, -70, 35 left superior parietal lobe 
pre faces > scrambled 2490 13.48 48, -34, 41 right supramarginal gyrus 
post faces > scrambled 2476 14.66 -33, -46, 44 left superior parietal lobe 
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For each cluster, voxel volume, maximum t-test value, voxel coordinates, and the main 
structures included in the cluster and only the peak activation were mentioned. For all results 
the height threshold was T = 5.451732 [p < 0.05t (FEW)], the extent threshold was k = 0 voxels. 
 
Figure 9: Left posterior cingulate gyrus (-3 -37 38), T: 13.48, KE: 1565; Peak activation (global maxima) in 
MDD patients before treatment during the presentation of afraid facial pictures compared to 
baseline. 
 
Figure 10: Right precuneus (PCu) (6, -40, 44 ), T:13.66, KE: 576; Peak activation (global maxima) in MDD 
patients after treatment during the presentation of afraid facial pictures compared to baseline. 
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Figure 11: Left anterior cingulate gyrus (-9 38 -4), T: 13.31, KE: 865; Peak activation (global maxima) in MDD 
patients before treatment during the presentation of angry facial pictures compared to baseline. 
 
Figure 12: Left posterior cingulate gyrus (-9, -37, 38), T: 13.28, KE: 2077; peak activation (global maxima) in 
MDD patients after treatment during the presentation of angry facial pictures compared to baseline. 
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Figure 13: Left posterior cingulate gyrus (0 -40 44), T: 14.40, KE: 2376; Peak activation (global maxima) in 
MDD patients before treatment during the presentation of happy facial pictures compared to 
baseline. 
 
Figure 14: Left posterior cingulate gyrus (0 -40 44), T: 12.83, KE: 3280; Peak activation (global maxima) in 
MDD patients after treatment during the presentation of happy facial pictures compared to baseline. 
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Figure 15: Left posterior cingulate gyrus (0 -40 44), T: 12.54, KE: 1917; Peak activation (global maxima) in 
MDD patients before treatment during the presentation of neutral facial pictures compared to 
baseline. 
 
Figure 16: Left posterior cingulate gyrus (-6 -40 41), T: 12.09, KE: 2091; Peak activation (global maxima) in 
MDD patients after treatment during the presentation of neutral facial pictures compared to baseline. 
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Figure 17: Left posterior cingulate gyrus (0 -40 44), T: 11.97, KE: 1868; Peak activation (global maxima) in 
MDD patients before treatment during the presentation of sad facial pictures compared to baseline. 
 
Figure 18: Left precuneus gyrus (0 -43 44), T: 13.20, KE: 2571; Peak activation (global maxima) in MDD 
patients after treatment during the presentation of sad facial pictures compared to baseline. 
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3.3. BOLD % signal change in MDD patients after short term treatment with 
antidepressants or placebo 
3.3.1. BOLD % signal change in the different ROIs of MDD patients: comparison 
of two treatment groups receiving antidepressants in comparison to placebo 
 
Figure 19: Clinical ratings (HAM-D21 scores), all medication (verum) treatment groups summarized (n = 24) 
vs. placebo (n = 9) before and after the fMRI scans (error bars ± SEM). 
3.3.1.1. BOLD % signal change in the left and right amygdala 
There was a statistically significant BOLD % signal change reduction after one week of short 
term treatment in the left amygdala during the presentation of angry (F [1, 32] = 4.73, p<0.037), 
happy (F [1, 32] = 4.76, p = 0.037), neutral (F [1, 32] = 5.89, p = 0.021), and sad (F [1, 32] = 
11.36, p = 0.002) facial expressions compared to baseline. The same was true for the right 
amygdala during presentation of happy (F [1, 32] = 6.58, p = 0.015), neutral (F [1, 32] = 6.12, 
p = 0.019), and sad (F [1, 32] = 5.28, p = 0.029) faces compared to baseline in both patient 
groups, the patients treated with agomelatine, escitalopram or mirtazapine and the placebo 
treated patient. There were no statistically significant differences between both treatment 
groups. 
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Figure 20: Statistically significant BOLD % signal change after treatment in the left and right amygdala during 
the presentation of emotional faces (a: angry; c, d: happy, e, f: neutral; g, h: sad) before and after 
treatment in both treatment groups (patients receiving antidepressants or placebo). In the right 
amygdala angry vs. baseline showed a nonsignificant trend (b). 
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The following statistically significant time effects were detected in the left amygdala after short 
term treatment with antidepressants or placebo during the presentation of afraid vs. neutral faces 
(rmANOVA: F [1, 32] = 5.56, p = 0.025), angry vs. neutral face (rmANOVA: F [1, 32] = 5.56, 
p = 0.025), happy vs. neutral faces (rmANOVA: F [1, 32] = 5.84, p = 0.022), sad vs. neutral 
faces (rmANOVA: F [1, 32] = 11.30, p = 0.002), sad faces vs. scrambled pictures (rmANOVA: 
F [1, 32] = 6.13, p = 0.019), angry vs. happy faces (rmANOVA: F [1, 32] = 6.67, p = 0.015), 
sad vs. happy faces (rmANOVA: F [1, 32] = 9.25, p = 0.005), and all faces vs. scrambled 
pictures (rmANOVA: F [1, 32] = 8.33, p = 0.007). 
In addition, in the right amygdala the same was true for the contrasts between afraid and neutral 
faces (rmANOVA: F [1, 32] = 5.20, p = 0.030), angry and neutral faces (rmANOVA: F [1, 32] 
= 5.92, p = 0.021), angry faces and scrambled pictures (rmANOVA: F [1, 32] = 5.55, p = 0.041), 
happy and neutral faces (rmANOVA: F [1, 32] = 8.53, p = 0.006), happy faces and scrambled 
pictures (rmANOVA: F [1, 32] = 7.46, p = 0.010), neutral faces and scrambled pictures 
(rmANOVA: F [1, 32] = 5.95, p = 0.021), sad and neutral faces (rmANOVA: F [1, 32] = 7.83, 
p=0.009), sad faces and scrambled pictures (rmANOVA: F [1, 32] = 5.45, p = 0.026), angry 
and happy faces (rmANOVA: F [1, 32] = 7.44, p = 0.010), sad and happy faces (rmANOVA: 
F [1, 32] = 7.96, p = 0.008), and all faces together compared to scrambled pictures (rmANOVA: 
F [1, 32] = 8.76, p = 0.006). But there were no significant group effects between the patients 
using antidepressant medication vs. the placebo treated patients in any one of the contrast. 
3.3.1.2. BOLD % signal change in the left and right DLPFC 
In the right DLPFC the BOLD % signal change was significantly reduced during the 
presentation of angry facial pictures (rmANOVA: F [1, 32] = 10.35, p = 0.003) after one week 
treatment (medication and placebo), but again, significant differences between antidepressant 
treated patients and the placebo group could not be detected. 
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Figure 21: Statistically significant BOLD % signal change after treatment in the right DLPFC during the 
presentation of angry faces before and after treatment in both treatment groups (patients receiving 
antidepressants or placebo).  
3.3.1.3. BOLD % signal change in the left and right fusiform gyrus 
In the left fusiform gyrus the BOLD % signal change in contrast to baseline significantly was 
significantly different during the presentation of sad faces (rmANOVA: F [1, 32] = 4.25, p = 
0.048) after the treatment, the same change could be detected in the right fusiform gyrus during 
the presentation of neutral faces (rmANOVA: F [1, 32] = 4.25, p = 0.048) and after sad facial 
expressions (rmANOVA: F [1, 32] = 4.69, p = 0.038) after one week of short term treatment. 
Here, we could detect a statistically significant difference between the two treatment groups 
(rmANOVA time * medication: F [1, 32] = 4.62, p = 0.040), because only in the placebo group 
a reduced BOLD % signal change was detected. 
Again, there was no statistically significant difference in other ROIs.  
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Figure 22: Statistically significant BOLD % signal change after treatment in the fusiform gyrus on 
both sides during the presentation of sad (a, b) and on the left side during the presentation 
of neutral faces (c) before and after treatment in placebo treated patients. All other 
differences were not statistically significant (a-d, right side, and d). 
In the left fusiform gyrus the following statistically significant time effects after short term 
treatment were detected during the presentation of afraid vs. neutral faces (rmANOVA: F [1, 
32] = 26.86, p = 0.000013), neutral faces vs. scrambled pictures (rmANOVA: F [1, 32] = 4.18, 
p = 0.050), sad vs. neutral faces (rmANOVA: F [1, 32] = 5.08, p = 0.031), sad faces vs. 
scrambled pictures (rmANOVA: F [1, 32] = 4.20, p = 0.049, and all faces together vs. scrambled 
pictures (rmANOVA: F [1, 32] = 21.23, p = 0.000006). No significant effects due to 
antidepressant medication or placebo could be detected. 
3.3.1.4. BOLD % signal change in the left and right insula 
In the left insula of MDD patients statistically significant time effects in the BOLD % signal 
change was detected during the presentation of angry vs neutral faces (rmANOVA: F [1, 32] = 
4.56, p = 0.041) and neutral faces in contrast to scrambled pictures (rmANOVA: F [1, 32] = 
4.56, p = 0.041). No significant effects of medication or placebo were detected. 
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3.3.2. BOLD % signal change in different ROIs of MDD patients: comparison of 
four treatment groups receiving agomelatine, escitalopram, mirtazapine or 
placebo 
In the next step the patients of all four treatment groups were analyzed separately to detect 
significant group effects of the three medication groups or the placebo group. Figure 23 is 
demonstrating the clinical development of all four treatment groups showing an overall 
significant reduction of the HAM-D21 sum scores (rmANOVA: F [1, 32] = 48.4, p < 0.001) 
without distinguishable significant differences between the treatment groups. 
 
Figure 23: Clinical ratings (HAM-D21 scores) in all four treatment groups before and after the fMRI scans 
(error bars ± SEM)  
3.3.2.1. BOLD % signal change in the left and right amygdala 
In the next chapter the BOLD % signal change in response to facial expressions and scrambled 
pictures after the subdivision of 33 MDD patients in four treatment groups (agomelatine, 
escitalopram, mirtazapine, or placebo) is illustrated. In all four groups the BOLD % signal 
change was significantly reduced in the left amygdala during the presentation of angry 
(rmANOVA: F [1, 32] = 6.33, p = 0.018) and sad faces (rmANOVA: F [1, 32] = 7.72, p = 
0.009). In addition, the BOLD % signal change was significantly reduced in the right amygdala 
during the presentation of happy facial pictures (rmANOVA: F [1, 32] = 7.11, p = 0.012). 
Amygdala BOLD response (mean ± standard error) to different pictures with emotional facial 
expressions in different conditions (emotional contrasts to baseline) in MDD patients. The 
conditions angry and sad were significantly different in the left amygdala  and condition happy 
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in the right amygdala after short-term treatment with antidepressants or placebo. The 
medication group had no significant influence 
 
Figure 24: Amygdala BOLD response (mean ± standard error) to different pictures with emotional facial 
expressions in different conditions (emotional contrasts to baseline) in MDD patients. The 
conditions angry (a) and sad (e) were significantly different in the left amygdala and the condition 
happy (d) in the right amygdala after short-term treatment with antidepressants or placebo. The 
conditions displayed on b, c, f showed no statistically significant differences. Also, the medication 
group had no significant influence. 
 57  
In the right amygdala of all four treatment groups during the presentation of angry compared to 
neutral faces (rmANOVA: F [1, 32] = 3.17, p = 0.086), angry faces in contrast to scrambled 
pictures (rmANOVA F [1, 32] = 4.52, p = 0.042), happy versus neutral faces (rmANOVA: F 
[1, 32] = 7.11, p = 0.012), happy faces compared to scrambled pictures (rmANOVA: F [1, 32] 
= 6.95, p = 0.013), and neutral faces in contrast to scrambled pictures (rmANOVA: F [1, 32] = 
4.31, p = 0.047) significant time effects after one week of antidepressant treatment could be 
detected. The same was true in the left amygdala during presentation of sad faces versus 
scrambled pictures (rmANOVA: F [1, 32] = 4.31, p = 0.047). No statistically significant group 
effects due to three different antidepressants or placebo could be calculated. 
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Figure 25: Statistically significant BOLD % signal change after treatment in the right amygdala during the 
presentation of angry vs. neutral faces (a), angry faces vs. scrambled pictures (b), happy vs. neutral 
faces (c), happy faces vs. scrambled pictures (d), and neutral faces vs. scrambled pictures could be 
detected. In the left amygdala there were significant changes during the presentation of sad faces vs. 
scrambled pictures.  
In addition, there are significant time effects in the left and right amygdala of all four MDD 
patient groups during the presentation of sad versus neutral faces (left amygdala: rmANOVA: 
F [1, 32] = 6.46, p = 0.017; right amygdala: rmANOVA: F [1, 32] = 4.50, p = 0.043), angry 
compared to happy faces (left amygdala: rmANOVA: F [1, 32] = 5.50, p = 0.026; right 
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amygdala: rmANOVA: F [1, 32] = 8.71, p = 0.006), sad in contrast to happy faces (left 
amygdala: rmANOVA: F [1,32] = 6.33, p = 0.018, right amygdala: rmANOVA: F [1, 32] = 
6.52, p = 0.016) and all facial expressions compared to scrambled pictures (left amygdala: 
rmANOVA: F [1, 32] = 5.30, p=0.029; right amygdala: rmANOVA: F [d1, 32] = 7.13, p = 
0.012). In all contrasts no significant group effects (three different antidepressants or placebo) 
could be detected. 
 
Figure 26: Statistically significant BOLD % signal change after treatment in the left and right amygdala during 
the presentation of angry vs. happy faces (a, b), sad vs. happy faces (c, d), and sad vs. neutral faces 
(e, f). 
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Figure 27: Statistically significant BOLD % signal change after treatment in the right amygdala during the 
presentation of happy (a), neutral (c), sad (e) and all (g) faces vs. scrambled pictures, angry (b) or 
happy (d) vs. neutral faces. In the left amygdala all faces vs. scrambled pictures showed a significant 
change (h). 
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3.3.2.2. BOLD % signal change in the left and right DLPFC 
In the right DLPFC significantly reduced % signal change during the presentation of angry 
faces compared to baseline (rmANOVA: F [1, 32] = 7.11, p = 0.012) were detected. No further 
significant differences in any contrasts or on the left side could be detected, neither any 
significant differences between the four different medication groups. 
 
Figure 28: Statistically significant BOLD % signal change after treatment in the right DLPFC during the 
presentation of angry faces in contrast to baseline. 
In the left DLPFC during the presentation of afraid compared to neutral faces (rmANOVA: F 
[1, 32] = 16.09, p = 0.00039) and during all emotional faces vs. scrambled pictures significant 
time effects were detected (rmANOVA: F [1, 32] = 31.38, p = 0.000081). Also in the right 
DLPFC during the presentation of angry in contrast to neutral faces (rmANOVA: F [1, 32] = 
7.21, p = 0.012), angry vs. happy faces (rmANOVA: F [1, 32] = 9.58, p = 0.004) and sad vs. 
happy faces significant time effects were confirmed (rmANOVA: F [1, 32] = 6.20, p = 0.019). 
But again, no significant effects of the treatment with either one of the antidepressants or 
placebo could be seen. 
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3.3.2.3. BOLD % signal change in the left and right fusiform gyrus 
In the left fusiform gyrus during presentation of afraid vs. neutral faces (rmANOVA: F [1, 32] 
= 35.74, p = 0.000002) and during the presentation of all faces in contrast to scrambled pictures 
significant time effects (rmANOVA: F [1, 32] = 39.16, p < 0.001) were confirmed. No 
significant effect of one of the four treatments were detected. 
Notably, there are no statistically significant effects in the hippocampus and in the insula in all 
four tretment groups could be detected after short-term antidepressant treatment. 
3.3.3. Correlation of the BOLD % signal change with the severity of depression 
(HAM-D21) in all ROIs and during all contrasts 
A significant decrease in the sum score of the HAM-D21 depression rating scale could be 
detected in the mean values of all 33 investigated patients already after one week of treatment 
(figure 2). This was also true for the comparison between all medicated patients with the 
placebo treated patients (figure 19). Also after the subdivision in all three medicated treatment 
groups and the placebo treated patients similarly a progression was evident in all groups (figure 
23). No clinically meaningful or statistically significant differentiation between the four 
treatment groups was possible after only one week of treatment. Possible correlations of the 
BOLD % signal change in different ROIs with the severity of depression measured using the 
HAM-D21 scale, were investigated using nonparametric and parametric correlations. First, 
correlations of the HAM-D21 sum score on day 1 with fMRI results (1st contrasts to baseline 
in all ROIs, 2nd contrasts between facial and scrambled pictures in all ROIs) of the first pre-
treatment fMRI session were calculated, then correlations on day 11 with fMRI results of the 
second post-treatment fMRI session were calculated. 
In the first step of this exploratory analysis the nonparametric Spearman's rank correlation 
coefficient (Spearman's rho) was calculated. Statistically significant correlations were 
described in the following section. All other correlations did not reach statistical significance 
(p<0.05). 
The pre-treatment HAM-D21 sum score on day 1 was correlated with the BOLD % signal 
change on the first pretreatment fMRI in the right DLPFC during the presentation of angry faces 
vs. baseline (Spearman's correlation coefficient = 0.452, p (two sided) = 0.008), in the right 
DLPFC during the presentation of neutral faces vs. baseline (= 0.392, p = 0.024), and in the 
right fusiform gyrus during sad faces vs. baseline (= 0.353, p = 0.044). 
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The HAM-D21 sum score after one week of treatment on day 11 was correlated with the BOLD 
% signal change on the second fMRI after one week of treatment in the left amygdala during 
the presentation of afraid faces vs. scrambled pictures (= 0.435, p = 0.011). 
In the second step of the exploratory analysis the Kolmogorov-Smirnov (K-S)-test was used to 
test for normal distribution (the significance level was set to p < 0.05). Not normally distributed 
were the following variables (BOLD % signal change) before treatment: right DLPFC (afraid 
faces vs. baseline), right insula (afraid faces vs. baseline), left DLPFC (angry faces vs. baseline), 
left DLPFC (neutral faces vs. baseline), and left DLPFC (scrambled vs. baseline). Also not 
normally distributed were the following variables after one week of treatment: right amygdala 
(happy faces vs. baseline), left DLPFC (happy faces vs. baseline), left hippocampus (happy 
faces vs. baseline), right hippocampus (happy faces vs. baseline), left DLPFC (sad faces vs. 
baseline), left hippocampus (sad faces vs. baseline), right hippocampus (sad faces vs. baseline), 
and left DLPFC (scrambled pictures vs. baseline). 
These variables were excluded from the following analysis using the parametric Pearson 
correlation coefficient (Pearson’s r) which can only be used with normally distributed variables. 
Statistically significant positive correlations of the BOLD % signal change with the HAM-D21 
score pre-treatment could be identified in the following normally distributed variables: right 
DLPFC angry faces vs. baseline (correlation coefficient r = 0.366, p = 0.036), right DLPFC 
neutral faces vs. baseline (r = 0.367, p = 0.036) and in the left amygdala scrambled pictures vs. 
baseline (r = 0.354, p = 0.043). The same was true for the positive correlation of the HAM-D21 
score with the BOLD % signal change in the left amygdala afraid faces vs. baseline (r = 0.378, 
p = 0.030). In these regions higher BOLD % signal changes were correlated with more severe 
depression. 
Investigating the correlations of 13 differential contrasts with the severity of depression using 
the nonparametric Spearman's rank correlation coefficient revealed the following positive and 
statistically significant correlations with the first pretreatment fMRI results: left DLPFC afraid 
vs. neutral faces (correlation coefficient = 0.383, p = 0.028), right DLPFC afraid- vs. neutral 
faces (= 0.370, p = 0.034, left DLPFC angry vs. neutral faces (= 0.420, p = 0.015), right 
DLPFC angry vs. neutral faces (= 0.429, p = 0.013), right DLPFC angry faces vs. scrambled 
pictures (= 0.434, p = 0.012), left DLPFC happy vs. neutral faces (= 0.365, p = 0.037), right 
DLPFC happy vs. neutral faces (= 0.385, p = 0.027), right DLPFC happy faces vs. scrambled 
pictures (= 0.363, p = 0.038), right DLPFC neutral faces vs. scrambled pictures (= 0.400, p 
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= 0.021), left DLPFC sad vs. neutral faces (= 0.412, p = 0.017), right DLPFC sad vs. neutral 
faces (= 0.394, p = 0.023), right DLPFC sad faces vs. scrambled pictures (= 0.412, p = 
0.017), left DLPFC afraid- vs. happy faces (= 0.370, p = 0.034), left DLPFC angry vs. happy 
faces (= 0.413, p = 0.017), right DLPFC angry vs. happy faces (= 0.452, p = 0.008), left 
DLPFC sad vs. happy faces (= 0.396, p = 0.022), right DLPFC sad vs. happy faces (= 0.390, 
p = 0.025), and the left DLPFC faces vs. scrambled pictures (= 0.408, p = 0.018). 
The HAM-D21 sum score on the post-treatment day 11 was positively correlated with the 
BOLD % signal change on the second fMRI after one week of treatment in the following ROIs 
and during the following contrasts: left amygdala (afraid faces vs. scrambled pictures 
(correlation coefficient = 0.384, p (two sided) = 0.027), and left amygdala afraid vs. happy 
faces (= 0.349, p = 0.047). 
The K-S test for normal distribution confirmed that the following variables (ROIs and contrasts) 
were not normally distributed before treatment and therefore excluded from the parametric 
correlative analysis: right amygdala (afraid vs. neutral faces), left DLPFC (afraid vs. neutral 
faces), left amygdala (angry vs. neutral faces), left DLPFC (angry vs. neutral faces), left 
amygdala (angry vs. neutral faces), left DLPFC (angry faces vs. scrambled pictures), left 
DLPFC (happy vs. neutral faces), left DLPFC (happy faces vs. scrambled pictures), left DLPFC 
(neutral faces vs. scrambled pictures), left DLPFC (sad vs. neutral faces), left hippocampus (sad 
vs. neutral faces), left DLPFC (sad faces vs. scrambled pictures), left hippocampus (sad faces 
vs. scrambled pictures), right hippocampus (afraid vs. happy faces), left hippocampus (afraid 
vs. happy faces), left amygdala (sad vs. happy faces), right amygdala (sad vs. happy faces), 
right DLPFC (sad vs. happy faces), and the left amygdala (faces vs. scrambled pictures) The 
same was true for the following post-treatment variables: right amygdala (afraid vs. neutral 
faces), left DLPFC (angry vs. neutral faces), right hippocampus (angry faces vs. scrambled 
pictures), left insula (angry faces vs. scrambled pictures), left DLPFC (happy vs. neutral faces), 
right DLPFC (happy vs. neutral faces), left hippocampus (happy vs. neutral faces), left DLPFC 
(happy faces vs. scrambled pictures), right hippocampus (happy faces vs. scrambled pictures), 
left DLPFC (neutral faces vs. scrambled pictures), right amygdala (sad vs. neutral faces), left 
hippocampus (sad vs. neutral faces), right hippocampus (sad vs. neutral faces), left DLPFC (sad 
faces vs. scrambled pictures), right hippocampus (sad faces vs. scrambled pictures), left DLPFC 
(afraid vs. happy faces), left hippocampus (afraid vs. happy faces), left DLPFC (angry vs. happy 
faces), left hippocampus (angry vs. happy faces), left DLPFC (sad vs. happy faces), right 
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DLPFC (sad vs. happy faces), left hippocampus (sad vs. happy faces), left DLPFC (faces vs. 
scrambled pictures), and the right DLPFC (faces vs. scrambled pictures). 
Using Pearson’s r in the remaining normally distributed variables the positive and statistically 
significant correlations of the BOD % signal change with the HAM-D21 score could be 
identified on the pre-treatment day 1 in the following ROIs and contrasts: right DLPFC afraid 
vs. neutral faces (correlation coefficient r = 0.366, p = 0.036), right DLPFC angry vs. neutral 
faces (r = 0.429, p = 0.013), right DLPFC angry faces vs. scrambled pictures (r = 0.390, p = 
0.025), right DLPFC happy vs. neutral faces (r = 0.391, p = 0.025), right DLPFC happy faces 
vs. scrambled pictures (r = 0.366, p = 0.036), right DLPFC neutral faces vs. scrambled pictures 
(r = 0.388, p = 0.026), right DLPFC sad vs. neutral faces (r = 0.368, p = 0.035), right DLPFC 
sad faces vs. scrambled pictures (r = 0.356, p = 0.042), right DLPFC angry vs. happy faces (r = 
0.401, p = 0.021), and the left DLPFC faces vs. scrambled pictures (r = 0.387, p = 0.026). 
3.3.4. Correlation of the BOLD % signal change with the HPA-axis activity 
(cortisol levels) in all ROIs and during all contrasts 
The subgrup of ten depressed patients investigated with the combined Dex/CRH-test under 
resting conditions on day 2 of the study before starting the antidepressant pharmacotherapy 
showed the typical profile of a marked cortisol stimulation after administration of CRH at 3:30 
pm. After one week of treatment, on day 10 of the study, the cortisol secretion was blunted 
slightly without showing statistically significant differences in comparison to the secretion 
profile on day 2 (figure 29). 
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Figure 29: Cortisol secretion (mean ± SEM in ng/ml) during the combined Dex/CRH-test before and after one 
week of antidepressant short-term treatment with agomelatine, escitalopram, mirtazapine or placebo. 
Slightly reduced cortisol secretion post-treatment (not significant, rmANOVA F [1, 32] = 0.39, p > 
0.05). No detectable differences between the treatment groups. 
For the correlative analyses first the AUCs representing the quantity of the cortisol secretion 
during the 75 minutes lasting combined Dex/CRH test, wer calculated. Comparing the total 
cortisol secretion before treatment and after one week of antidepressant treatment with three 
antidepressants or placebo, the descriptive analysis showed a cortisol reduction which did not 
reach statistically significance (figure 30). 
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Figure 30: Cortisol secretion during the combined Dex/CRH-test (mean AUC ± SEM in ng/ml*75min) before 
and after one week of antidepressant short-term treatment with agomelatine, escitalopram, 
mirtazapine or placebo. AUC and baseline corrected AUC. Slightly reduced cortisol secretion post-
treatment (not statistically significant, n.s.). 
Interestingly, in spite of the lack of statistical significance, the following figures (figure 31, 
figure 32, and figure 33) are showing differential reactions of the cortisol secretion which were 
consistent in all three analyses. Analyzing the peak cortisol levels and the AUCs with and 
without baseline correction an increase of the cortisol secretion after one week in the 
escitalopram group and decreasing cortisol secretions in all other groups (mirtazapine, 
agomelatine, and placebo) could be detected. 
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Figure 31: Cortisol secretion during the combined Dex/CRH-test (mean peak ± SEM in ng/ml) before and after 
one week of antidepressant short-term treatment with agomelatine, escitalopram, mirtazapine or 
placebo. No statistically significant differences before and after treatment and between different 
medication groups. Differential influence on cortisol in different treatment groups (n.s.). 
 
Figure 32: Cortisol secretion during the combined Dex/CRH-test (mean AUC ± SEM in ng/ml*75min) before 
and after one week of antidepressant treatment with agomelatine, escitalopram, mirtazapine or 
placebo. No statistically significant differences before and after treatment and between different 
medication groups. Differential influence on cortisol in different treatment groups (n.s.). 
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Figure33: Cortisol secretion during the combined Dex/CRH-test (mean AUCbc ± SEM in ng/ml*75min) before 
and after one week of antidepressant treatment with agomelatine, escitalopram, mirtazapine or 
placebo. No statistically significant differences before and after treatment and between different 
medication groups. Differential influence on cortisol in different treatment groups (n.s.).  
Because some of the investigated variables were not normally distributed, for the correlative 
analysis again first the nonparametric Spearman's rank correlation coefficient (Spearman's rho) 
was calculated. Statistically significant correlations were described in the following section. 
The nonparametric Spearman's rank correlation coefficient (Spearman's rho) was calculated. 
Significant correlations could be found for the variables described in the following paragraph. 
All other correlations did not reach statistical significance (p < 0.05). 
No pretreatment Dex/CRH test results were correlated with the BOLD % signal change in any 
ROI and any contrast vs. baseline. The results of the second combined Dex/CRH test after one 
week of antidepressant treatment (AUC, AUCbc, peak) were correlated with the BOLD % signal 
change on the second posttreatment fMRI in the following ROIs and contrasts: right amygdala 
(afraid faces vs. baseline) was correlated with cortisol AUC (correlation coefficient = -0.745, 
p (two sided) = 0.021) and with the cortisol peak (= -0.695, p = 0.038). The right hippocampus 
(afraid faces vs. baseline) was correlated with cortisol AUC (= -0.867, p = 0.002), AUCbc 
(= -0.750, p = 0.020), and cortisol peak values (= -0.900, p = 0.001). The left hippocampus 
(neutral faces vs. baseline) was correlated with cortisol AUCbc (= -0.783, p = 0.013), and the 
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right hippocampus (neutral faces vs. baseline) was correlated with cortisol AUCbc (= -0.667, 
p = 0.050). 
Calculating the contrasts between different emotional and neutral faces and scrambled pictures 
in the predefined ROIs and calculating the nonparametric Spearman's rank correlation 
coefficients with the first pre-treatment Dex/CRH test, only a single significant correlation of 
the BOLD % signal change in the right DLPFC after the presentation of afraid vs. happy faces 
with cortisol AUCbc (= -0.703, p = 0.035) could be detected. 
The second Dex/CRH test showed more correlations with fMRI results after one week of 
treatment. The following nonparametric correlations of the combined Dex/CRH test after 
treatment (AUC, AUCbc, peak) with the BOLD % signal change could be found: right fusiform 
(afraid vs. neutral faces) was correlated with cortisol AUCbc (= -0.683, p = 0.042); the left 
hippocampus (afraid vs. neutral faces) was significantly correlated with cortisol AUC (= -
0.700, p = 0.036), AUCbc (= -0.783, p = 0.013), and the cortisol peak values (= -0.750, p = 
0.020); the right hippocampus (afraid vs. neutral faces) was significantly correlated with 
cortisol AUC (= -0.767, p = 0.016), AUCbc (= -0.667, p = 0.050), and the cortisol peak 
values (= -0.783, p = 0.013); the right DLPFC (angry vs. neutral faces) was significantly 
correlated with cortisol AUC (= -0.783, p = 0.013), AUCbc (= -0.683, p = 0.042), and the 
cortisol peak values (= -0.733, p = 0.025); the right DLPFC (happy vs. neutral faces) was 
significantly correlated with cortisol AUC (= 0.817, p = 0.007), and the cortisol peak values 
(= 0.733, p = 0.025); the right hippocampus (happy vs. neutral faces) was significantly 
correlated with cortisol AUC (= -0.678, p = 0.045), AUCbc (= -0.703, p = 0.035), and the 
cortisol peak values (= -0.695, p = 0.038); the right DLPFC (happy faces vs. scrambled 
pictures) was significantly correlated with the cortisol AUC (= -0.667, p =0 .050); the right 
DLPFC (neutral faces vs. scrambled pictures) was significantly correlated with the cortisol 
AUC (= -0.733, p = 0.025); the right DLPFC (sad vs. neutral faces) was significantly 
correlated with the cortisol AUC (= -0.733, p = 0.025); the right DLPFC (sad faces vs. 
scrambled pictures) was significantly correlated with cortisol AUC (= -0.667, p = 0.050), and 
the AUCbc (= -0.667, p = 0.050), the right fusiform (afraid vs. happy faces) was significantly 
correlated with cortisol AUCbc (= -0.717, p = 0.030); the left hippocampus (afraid vs. happy 
faces) was significantly correlated with cortisol AUC (= -0.711, p = 0.032); the right DLPFC 
(angry vs. happy faces) was significantly correlated with cortisol AUC (= 0.800, p = 0.010), 
and the cortisol peak values (= 0.733, p = 0.025), the right DLPFC (sad vs. happy faces) was 
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significantly correlated with cortisol AUC (= 0.717, p = 0.030); and the right DLPFC (faces 
vs. scrambled pictures) was significantly correlated with cortisol AUC (= 0.717, p = 0.030). 
To prevent from information loss due to the nonparametric procedure in a further analysis it 
was calculated whether some of our investigated variables were not normally distributed to be 
able to calculate the parametric Pearson correlation coefficient for the detection of 
interdependencies between the HPA-axis activity and the fMRI results. 
The test for normal distribution (Kolmogorov-Smirnov (K-S)-test, p < 0.05) revealed, that the 
results of the Dex/CRH test before treatment are not normally distributed: cortisol AUC and 
AUCbc (ng/ml*75min). The pre-treatment fMRI results showed no normal distribution in the 
following ROIs and contrasts: right DLPFC (afraid faces vs. baseline), right insula (afraid faces 
vs. baseline), left DLPFC (angry faces vs. baseline), left DLPFC (happy faces vs. baseline), left 
DLPFC (neutral faces vs. baseline), left DLPFC (scrambled pictures vs. baseline), right 
amygdala (afraid vs. neutral faces), left DLPFC (afraid vs. neutral faces), left amygdala (angry 
vs. neutral faces), left DLPFC (angry vs. neutral faces), left DLPFC (angry faces vs. scrambled 
pictures), left DLPFC (happy vs. neutral faces), left DLPFC (neutral faces vs. scrambled 
pictures), left DLPFC (sad vs. neutral faces), left hippocampus (sad vs. neutral faces), left 
hippocampus (sad faces vs. scrambled pictures), right hippocampus (afraid vs. happy faces), 
left hippocampus (afraid vs. happy faces), left amygdala (sad vs. happy faces), right amygdala 
(sad vs. happy faces), right DLPFC (sad vs. happy faces), and left amygdala (faces vs. 
scrambled pictures). 
After one week of treatment the following fMRI activity levels were not normally distributed: 
right amygdala (happy vs. baseline), left DLPFC post (happy vs. baseline), left hippocampus 
post (happy vs. baseline), right hippocampus post (happy vs. baseline), left hippocampus post 
(sad vs. baseline), right hippocampus post (sad vs. baseline), left insula post (sad vs. baseline), 
and left DLPFC post (scrambled pictures vs. baseline), left DLPFC (angry vs. neutral faces), 
left DLPFC (angry faces vs. scrambled pictures), right hippocampus (angry faces vs. scrambled 
pictures), left insula (angry faces vs. scrambled pictures), left DLPFC (happy vs. neutral faces), 
right DLPFC (happy vs. neutral faces), left hippocampus (happy vs. neutral faces), left DLPFC 
(happy faces vs. scrambled pictures), left hippocampus (happy faces vs. scrambled pictures), 
right hippocampus (happy faces vs. scrambled pictures), left DLPFC (neutral faces vs. 
scrambled pictures), right amygdala (sad vs. neutral faces), left DLPFC (sad vs. neutral faces), 
left hippocampus (sad vs. neutral faces), right hippocampus (sad vs. neutral faces), left DLPFC 
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(sad faces vs. scrambled pictures), right hippocampus (sad faces vs. scrambled pictures), left 
DLPFC (afraid vs. happy faces), left hippocampus (afraid vs. happy faces), left DLPFC (angry 
vs. happy faces), left hippocampus (angry vs. happy faces), left DLPFC (sad vs. happy faces), 
right DLPFC  (sad vs. happy faces), left hippocampus (sad vs. happy faces), left DLPFC (faces 
vs. scrambled pictures), and right DLPFC (faces-scrambled pictures). 
Using the Pearson correlation coefficient (Pearson’s r) for the remaining normally distributed 
variables the following statistically significnat correlations could be identified before treatment: 
left amygdala (happy faces vs. baseline) was correlated significantly with the cortisol AUCbc (r 
= -0.702, p = 0.035); right insula (scrambled pictures vs. baseline) was correlated significantly 
with the cortisol AUC (r = -0.685, p = 0.042) and the cortisol peak value (r = -0.670, p = 0.048); 
left amygdala (afraid faces vs. scrambled pictures) was correlated significantly with the cortisol 
AUC (r = -0.699, p = 0.036); left amygdala (happy faces vs. scrambled pictures) was correlated 
significantly with the cortisol AUC (r = -0.690, p = 0.040) and AUCbc (r = -0.739, p = 0.023); 
left amygdala (angry vs. happy faces) was correlated significantly with the cortisol AUCbc (r = 
-0.680, p = 0.044); the left amygdala (faces vs. scrambled pictures) was correlated significantly 
with the cortisol AUCbc (r = -0.695, p = 0.038). After one week of treatment the following 
BOLD % signal changes of the second fMRI were correlated significantly with the results of 
the Dex/CRH-test: the right hippocampus (afraid vs. neutral faces) was correlated significantly 
with the cortisol AUC (r = -0.712, p = 0.031), the AUCbc (r = -0.746, p = 0.021), and the cortisol 
peak values (r = -0.767, p = 0.016); the right DLPFC (angry vs. neutral faces) was correlated 
significantly with the cortisol AUC (r = -0.676, p = 0.046), the AUCbc (r = -0.678, p = 0.045), 
and the cortisol peak values (r = -0.674, p = 0.046); the right hippocampus (happy vs. neutral 
faces) was correlated significantly with the cortisol AUCbc (r = -0.702, p = 0.035); the right 
DLPFC post (happy faces vs. scrambled pictures) was correlated significantly with the cortisol 
AUC (r = -0.721, p = 0.029), the AUCbc (r = -0.673, p = 0.047), and the cortisol peak values (r 
= -0.720, p = 0.029); the right DLPFC post (neutral faces vs. scrambled pictures) was correlated 
significantly with the cortisol AUCbc (r = -0.673, p = 0.047), and the cortisol peak values (r = -
0.676, p = 0.045); the right DLPFC (sad vs. neutral faces) was correlated significantly with the 
cortisol AUCbc (r = -0.744, p = 0.022), and the cortisol peak values (r = -0.671, p = 0.048); the 
right hippocampus post-treatment (sad vs. neutral faces) was correlated significantly with the 
cortisol AUCbc (r = -0.681, p = 0.044); the right DLPFC (sad faces vs. scrambled pictures) was 
correlated significantly with the cortisol AUCbc (r = -0.693, p = 0.038); the right DLPFC (angry 
vs. happy faces) was correlated significantly with the cortisol AUC (r = -0.727, p = 0.026), and 
the cortisol peak values (r = -0.702, p = 0.035); right DLPFC (sad vs. happy faces) was 
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correlated significantly with the cortisol AUC (r = -0.698, p = 0.037), the AUCbc (r = -0.732, p 
= 0.025), and the cortisol peak values (r = -0.698, p = 0.036); and the right DLPFC (faces vs. 
scrambled pictures) was correlated significantly with the cortisol AUCbc (r = -0.705, p = 0.034), 
and the cortisol peak values (r = -0.687, p =0.041). 
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4. Discussion 
4.1. Facial processing in major depressed patients 
In principal, this pharmaco-fMRI study focused on the effects of antidepressant short term 
treatment on the processing of facial emotional pictures in major depressed patients. This 
represents a neurocognitive assessment target because a huge amount of evidence has shown 
that major depressed patients exhibited an impaired facial processing. They show bias in 
interpreting facial expressions, which may cause interrelationship difficulties (Fu, Williams et 
al. 2004). There are several published studies targeting facial processing, but the role of facial 
processing impairment in MDD patients in relation to HPA axis hyperactivity and to the 
severity of depression and it´s amelioration in an early stage of the treatment so far is not clear. 
Therefore, the research presented here first considers neurological aspects of the central nervous 
processing of emotional expressions, later it focuses on the combination of biological and 
clinical assessments to elucidate early effects of antidepressant treatment on the investigated 
systems. Thus, it bridges the gap between biological, behavioral and neurological aspects of 
depression to provide a better understanding of mechanisms facilitating pathophysiological 
changes due to MDD and during the first reduction of depressive symptoms. This may be 
helpful for the development of treatment options such as antidepressant medication or 
nonpharmacological treatments such as transcranial magnetic stimulation or neurofeedback. 
Specifically, this study investigated the effects of antidepressant treatments on BOLD % signal 
change in the amygdala, DLPFC, hippocampus, fusiform gyrus and insula as brain regions of 
interest during the presentation of afraid, angry, happy, neutral, and sad faces or scrambled 
pictures at the baseline before treatment and after one week of antidepressant treatment. 
During the recent years with further development of neuroimaging techniques a strong support 
was provided for a critical role of the amygdala in emotional processing. Haxby and Gobbini 
mentioned in their review (Rhodes, Calder et al. 2012) that the amygdala is critical for fear 
conditioning, but also it seems to involve more than only mirroring the emotion of fear. The 
amygdala can be engaged by positive emotions and positive experiences. Originally Whalen et 
al. suggested, that the amygdala is part of a vigilance system that is activated in ambiguous 
situations with biological relevance (Whalen, Rauch et al. 1998). Therefore, the ambiguity, not 
the emotion of fear, is the essential factor and can be positive or negative. 
The results of the study show that the BOLD % signal change in the left amygdala was 
significantly reduced during the presentation of angry, happy and sad facial expressions in 
contrast to baseline after one week of antidepressant treatment (figure 3a, b).It was also 
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significantly reduced during the presentation of emotional faces (afraid, angry, happy and sad) 
in contrast to neutral faces or scrambled pictures and during the processing of negative facial 
expressions (afraid, angry and sad) in contrast to happy faces (figure 4a). In addition, the BOLD 
% signal change in the right amygdala was significantly decreased during the presentation of 
happy and neutral facial expressions in contrast to baseline (figure 3c). The same was true 
during the processing of emotional facial expressions (afraid, angry, happy, and sad) in contrast 
to neutral faces or to scrambled pictures and during the processing of negative facial expressions 
(afraid, angry, and sad) in contrast to happy faces (figure 4b). 
As described above, it seems that the amygdala BOLD response to all facial emotional and 
neutral expressions in the post fMRI sessions was reduced. Therefore, this study suggests that 
hyperactivities in the amygdala of depressed patients even after one week of short term 
antidepressant treatment show a trend to normalize and to be significantly reduced during 
emotional and neutral facial expression processing. The current findings are consistent with 
other pharmaco-fMRI studies in emotional face processing in MDD patients (Sheline, Barch et 
al. 2001, Sergerie, Chochol et al. 2008). For example, Sheline et al. applied in their fMRI study 
the masked faces paradigm to MDD patients and matched control subjects to compare the 
amygdala activation in response to masked emotional faces before and after antidepressant 
treatment. At baseline, MDD patients showed exaggerated left amygdala activation to all faces, 
and even a greater activity during the presentation of fearful faces, while the right amygdala 
was not different between the patients and the placebo control group. After eight weeks of 
antidepressants treatment, MDD patients had bilateral reduced amygdala BOLD response to 
masked fearful faces and bilateral reduced amygdala BOLD response to all faces. Moreover, 
Sergerie et al. confirm 2008 in their metanalysis of fMRI studies of visual emotional perception, 
that the amygdala is associated to both, positive and negative stimuli with a preference for faces 
depicting emotional expressions (Sergerie, Chochol et al. 2008). 
The role of the prefrontal cortex and pattern activity of the left and right DLPFC in MDD 
patients were discussed in several fMRI investigations (Liotti, Mayberg et al. 2002, Keedwell, 
Andrew et al. 2005, Grimm, Beck et al. 2008). Those studies provide a consistent hypothesis 
in which MDD is associated with hypoactivity in the left DLPFC and hyperactivity in the right 
DLPFC. In their study especially Grimm et al. point to an imbalance of the neural activities in 
the right and left DLPFC (Grimm, Beck et al. 2008), which demonstrates that the left DLPFC 
hypoactivity is related to emotional judgement with abnormal modulation by positive and 
negative emotional valence. Furthermore, in this study hyperactivity in the right DLPFC was 
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associated with attentional modulation of emotional judgement. Mostly, the hypothesis of an 
imbalance of the activity in the left and right DLPF in MDD was based on repetitive transcranial 
magnetic stimulation (rTMS) studies. In these studies, stimulating rTMS (high frequency 10 
Hz rTMS) activates the hypoactive left DLPFC, whereas suppressing TMS (low frequency 1 
Hz rTMS) decreases neural activity in the hyperactive right DLPFC (Sackeim, Prohovnik et al. 
1993, Mottaghy, Keller et al. 2002). The imbalance of neural activities between the right and 
left DLPFC was also registered during the procession of facial expressions in our MDD patient 
sample. The analysis of the BOLD % signal change in the left DLPFC was significantly 
enhanced during the presentation of afraid faces compared to neutral faces after short term 
treatment. Also, in the right DLPFC the BOLD % signal change was significantly reduced 
during the presentation of afraid faces versus baseline and angry compared to neutral faces or 
to scrambled pictures, as well as during the presentation of happy versus neutral faces. In 
addition, in right DLPFC the BOLD % signal change was significantly reduced during the 
presentation of angry and sad compared to happy faces. In fact, our results show that neural 
hyperactivities in the right DLPFC of MDD patients tend to normalize and are reduced even 
after only one week of antidepressant treatment. Because the activity (BOLD % signal change) 
is also reduced in the placebo treated patient group (figure 5b, figure 6b), this effect seems to 
be independent from the kind of pharmacological or supportive treatment. 
This result is consistent with other neuroimaging and rTMS studies showing therapeutic effects 
in the right DLPFC associated with reduced neural activities in this brain region (Mottaghy, 
Keller et al. 2002, Grimm, Beck et al. 2008). 
According to Haxby et al. the fusiform gyrus is the brain region with the most replicated 
findings in facial expression studies (Haxby, Hoffman et al. 2002). The perception of faces has 
consistently been found to stimulate activity in the lateral fusiform gyrus usually bilateral, but 
more consistently on the right side (Haxby, Ungerleider et al. 1999). Our results show that the 
BOLD % signal change was significantly reduced in the right fusiform gyrus (figure 7) during 
the presentation of neutral faces versus baseline. The same was true in the left fusiform during 
presentation of afraid faces versus neutral after one week of treatment. 
Phan et al. reviewed 55 PET and fMRI activation studies and observed in a meta-analyses of 
neuroimaging studies on emotion that the medial prefrontal cortex had a main role in emotional 
processing (Phan, Wager et al. 2002). Sad condition induced activity in the subcallosal 
cingulate. Emotional induction by a visual task activated the occipital cortex and the amygdala. 
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Emotional recall/imagery were associated with the anterior cingulate and the insula, emotional 
stimuli with cognitive demand also involved the same regions (Phan, Wager et al. 2002). 
In our study a visual task including gender recognition targeted emotional processing and 
focused on predefined brain regions of interest. In addition, with a whole brain analysis we 
investigated the peak activation in brain regions associated with emotional facial processing 
during the presentation of facial emotional picture stimuli (table 3). The results show the most 
significantly activated region (BOLD signal) was located in the left posterior cingulate gyrus 
as a highest BOLD response to different facial emotional conditions in contrasts to baseline 
before and after treatment. But also in the left angular gyrus a significant BOLD signal was 
detected and in the left anterior cingulate gyrus and bilateral precuneus we registered the 
greatest BOLD response to emotional facial expression before and after short term treatment 
(figures 9-18). 
These study results are in line of other neuroimaging studies demonstrating the critical role of 
the posterior cingulate gyrus (Phan, Wager et al. 2002, Leech, Braga et al. 2012, Yang, Deng 
et al. 2015). Also Leech et al. suggest that the posterior cingulate cortex is a main node within 
the default mode network (DMN) and has great metabolic activity and dense structural 
connectivity to all other brain regions. Moreover, they have reported that the region appears to 
be induced by internally directed thought, for example, memory recollection. Even though, they 
suggest that the posterior cingulate has a complex function collecting and processing 
information from multiple other brain networks in overlapping regions (Leech, Braga et al. 
2012). In fact, mostly ventral regions show strong functional connectivity to the other parts of 
the DMN, while subregions in the dorsal posterior cingulate cortex are connected to 
frontoparietal networks which are involved in cognitive control. Therefore, it was suggested, 
that “parts of the dorsal posterior cingulate cortex are interacting with frontoparietal networks 
to regulate the balance between internally and externally directed cognition” (Leech, Braga et 
al. 2012). In addition, Hamani et al. reported in their review published 2011 that the subcallosal 
cingulate gyrus (SCG), including Brodmann area 25 (area in cerebral cortex), parts of area 24 
(part of anterior cingulate gyrus) and area 32 (also known as the dorsal anterior cingulate), is 
the portion of the cingulum that lies ventral to the corpus callosum (Hamani, Mayberg et al. 
2011). It involved a critical node in a network that includes cortical structures, the limbic 
system, thalamus, hypothalamus, and brainstem nuclei. Also researchers armed with a body of 
functional neuroimaging have reported abnormal SCG metabolic activities in depressed 
patients, which are changed and show a reversed pattern activation in this regions after 
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antidepressant therapies (Hamani, Mayberg et al. 2011). Also Mayberg et al. observed in a 
positron emission tomography (PET) study a relationship between changes in metabolism in 
the SCC and the response to antidepressant medications (Mayberg, Lozano et al. 2005). 
Table 4: BOLD % signal change after one week of treatment in predefined ROIs after emotional or neutral 
faces or scrambled pictures vs. baseline. Summary of results (* significant changes (rmANOVA, 
p<0.05);  = reduced BOLD % signal change,  = increased BOLD% signal change). 
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afraid vs. 
baseline           
angry vs. 
baseline           
happy vs. 
baseline           
neutral vs. 
baseline           
sad vs. 
baseline           
scrambled 
pictures vs. 
baseline 
          
In summary, our results demonstrate a reduced BOLD response to emotional and neutral visual 
stimuli in the bilateral amygdala, right dorsolateral and right fusiform gyrus while the clinical 
outcome measured with the Hamilton rating scale for depression indicated even after a short 
treatment period of only one week beneficial effects of the treatment independent of the 
treatment group including also placebo treated patients. 
Also, a meta-analysis of neuroimaging studies using fMRI and PET in MDD patients employing 
emotional stimuli provocation reported an enhanced activation of dorsolateral, dorsomedial and 
ventrolateral prefrontal cortices (Delaveau, Jabourian et al. 2011). In addition, the activation of 
the amygdala, hippocampus, parahippocampal region, ventral anterior cingulate cortex, 
orbitofrontal cortex, and insula associated with emotional stimuli was decreased after 
antidepressant treatment. Furthermore, they reported a decreased BOLD signal in the anterior 
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and posterior cingulate cortices, as well as in the precuneus and inferior parietal lobe, which 
could possibly reflect a restored deactivation of the DMN (Delaveau, Jabourian et al. 2011). 
4.2. Effects of antidepressant medication versus placebo treatment 
Imaging effects of antidepressants in comparison to placebo treatment were replicated in 
pharmaco fMRI studies and a variety of other imaging techniques quite consistently 
(Miskowiak, Favaron et al. 2009, Harmer, de Bodinat et al. 2011, Godlewska, Norbury et al. 
2012). Studies in healthy volunteers predominantly used a single dose stimulation design with 
antidepressant medication compared to placebo to explore mechanisms of action of the 
medication within the CNS (Maron, Wall et al. 2016). Also designs using a treatment duration 
of one week or even longer have been published (Maron, Wall et al. 2016). The crucial question 
is, whether results obtained in healthy volunteers can be translated to patients suffering from 
MDD, because some pharmaco-fMRI studies report evidence for differential effects of 
antidepressants on the CNS of healthy subjects or depressed patients. For example, Victor et al. 
investigated the amygdala response to sad, happy, and neutral faces in unmedicated participants 
suffering from MDD and in healthy controls (Victor, Furey et al. 2010). In this study major 
depressed patients showed a greater amygdala response than heathy controls to masked sad 
faces, whereas heathy controls showed a greater amygdala response to masked happy faces 
(Victor, Furey et al. 2010). Notably, by the time of the second fMRI, most of the patients 
showed clinically significant symptomatic improvement. This results also was confirmed by 
other authors (Fu, Williams et al. 2004). Furthermore, Lisiecka et al. studied the neural 
correlates of emotion processing and attention shifting in four groups; two groups were MDD 
patients with and without family history of depression and two groups were healthy controls 
with and without family history of depression (Lisiecka, Carballedo et al. 2013). They found 
that depressed patients with family history of MDD have stronger neural activation in 
subcortical areas during shifting attention from negative stimuli compared to healthy controls 
and depressed patients without family history of MDD who had less activation in the paralimbic 
regions and greater activation in core limbic areas, especially during emotion processing. 
Moreover, healthy controls with first-degree MDD relatives overactivated the somatosensory 
cortex and the attention controlling areas during both, emotion processing and attention shifting. 
There is also a fMRI study showing effects of erythropoietin in comparison to placebo on the 
neural processing of emotion in depressed patients after 3 days of treatment. In addition, 
erythropoietin caused memory improvement distinguishable from placebo treated patients 
(Miskowiak, Favaron et al. 2009). 
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In our study we compared patients treated with one of three antidepressants with placebo treated 
patients without specific medication. The results show a significant time effect and also reduced 
BOLD signal change after one week of treatment in the left amygdala during the presentation 
of angry, happy, neutral and sad faces (each condition in contrast to baseline). In the right 
amygdala the same was true during the presentation of happy, neutral, and sad faces (each 
condition again versus baseline) (figure 20a-h). We could detect significant treatment effects in 
the right DLPFC (figure 21) in the fMRI session during the presentation of angry faces after 
one week of treatment. Interestingly, significant treatment effects in the left and right fusiform 
gyrus were detected during the presentation of sad faces and in the left fusiform gyrus during 
the presentation of neutral faces only in the placebo treated patient group (figure 22a-c).  
Using pharmaco-fMRI we could demonstrate statistically significant pre-/post-treatment effects 
as described above, but we could not distinguish between medicated and unmedicated (placebo 
treated) patients. This may be due to the relatively small sample size or due to unspecific 
treatment effects which were similar in all treatment groups. Depression symptoms improved 
significantly after only one week of treatment also in the placebo treated patient group. Due to 
ethical reasons all patients received a similar amount of counseling and psychotherapy which 
contributed together with the unspecific relief of depressive symptoms due to the admission to 
the hospital. The changes seen in our fMRI investigation may also be more a state marker 
reflecting this reduction of depressive symptoms than a specific effect caused only in the group 
of medicated patients. 
4.3. Effects of agomelatine, escitalopram, mirtazapine or placebo treatment 
Harmer et al. studied the effects of administration of the antidepressant agomelatine or placebo 
over seven days on the emotional processing in healthy volunteers. The results show that 
agomelatine decreased subjective ratings of sadness together with the recognition of sad facial 
expressions. In addition, it improved positive affective memory compared to the placebo group 
(Harmer, de Bodinat et al. 2011). 
There is a pharmaco- fMRI study report from Maron et al. (2016) employing facial expression 
stimuli on healthy volunteers before and after one week of treatment using the SSRI 
escitalopram in comparison to an unmedicated group of healthy controls. The results show a 
significant activation reduction to fearful, but not to happy facial expressions bilaterally in the 
amygdala, the cingulate and the right medial frontal gyrus following escitalopram medication 
(Maron, Wall et al. 2016). There are similarities and differences between this study from Maron 
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et al. and our findings in depressed patients. There was a BOLD % signal reduction in our study 
during both conditions, afraid and happy faces in the left and right amygdala after short-term 
treatment. 
Studies in healthy subjects using one week of SSRI treatment revealed the same results of 
decreased amygdala activation during negative facial stimuli (Harmer, Mackay et al. 2006, 
Anderson, Del-Ben et al. 2007, Windischberger, Lanzenberger et al. 2010). Moreover, the 
amygdala activation was enhanced during the presentation of positive facial stimuli. These 
results could be replicated also another study in healthy volunteers published by Norbury et al. 
2009. In an pharmaco fMRI study a group of healthy volunteers showed increased amygdala 
activation during the stimulation with happy faces without changes in the levels of mood or 
anxiety after a short term treatment with citalopram (in comparison to placebo) (Norbury, 
Taylor et al. 2009). 
Therefore, it was not expected that in our study MDD patients treated with the SSRI 
escitalopram would reveal a reduced BOLD % signal change after one week of treatment in the 
amygdala response to happy facial expression stimuli. But our result is in line with other 
pharmaco-fMRI studies in MDD showing a decreased amygdala activation during the 
presentation of both, positive and negative conditions (which is different from studies in healthy 
controls) (Godlewska, Norbury et al. 2012). Godlewska et al. investigated the effects of short-
term SSRI treatment on the neural response to fearful faces in depressed patients (Godlewska, 
Norbury et al. 2012). MDD patients received SSRI treatment or placebo. The neural response 
to fearful and happy faces was investigated after 7 days of treatment. They could demonstrate, 
that amygdala responses to fearful facial expressions were significantly greater in depressed 
patients in contrast to healthy controls. Even though, exaggerated amygdala response to fearful 
faces was normalized in MDD patients after short treatment. Interestingly, after 7 days there 
was no significant difference in clinical depression ratings between patient treated with placebo 
or escitalopram. 
Whether the neural activation in response to facial expression stimuli changes in the depressed 
patients after treatment with longer duration was not demonstrated up to now, but a behavioral 
study in depressed patients receiving the SSRI citalopram or the NARI reboxetine has reported 
significant increases in recognition accuracy of disgust, happiness and surprise. This occurred 
after two weeks of antidepressant treatment, after six weeks the results were the same. 
Interestingly the fMRI results showed a significant correlation with the clinical improvement 
after six weeks of treatment (Tranter, Bell et al. 2009). 
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Pharmaco-fMRI studies considering the effects of the NaSSA Mirtazapine in healthy volunteers 
have shown an altered facial emotion processing even after the administration of a single-dose 
(Rawlings, Norbury et al. 2010, Komulainen, Heikkila et al. 2016). Rawlings et al. applied 
facial emotional stimuli after a single dose of mirtazapine or placebo in healthy volunteers. 
Finally, the mirtazapine treated group have shown significantly reduced BOLD response to 
fearful or angry faces and an increased BOLD response to happy facial expressions (Rawlings, 
Norbury et al. 2010). 
Another fMRI study investigated the effects of a single dose of mirtazapine on processing of 
self-referential emotional information on healthy volunteers in comparison to a healthy control 
group. During the fMRI the participants categorized positive and negative self-referential 
adjectives. Mirtazapine reduced the BOLD response to positive self-referential processing in 
the posterior cingulate cortex and in the parietal cortex (Komulainen, Heikkila et al. 2016). 
In contrast, a pharmaco-fMRI study investigated effects of emotional processing in depressed 
patients before and after 4 weeks of antidepressants treatments with mirtazapine or venlafaxine 
compared to healthy controls. Patients have shown an enhanced activation in the anterior 
cingulate cortex, the dorsomedial prefrontal cortex, the dorsolateral prefrontal cortex, and basal 
ganglia. In addition, a significant decrease of BOLD responses was seen in the hippocampus, 
basal ganglia, thalamus, and the cerebellum of venlafaxine-treated patients, and a significant 
enhanced BOLD responses was seen in the middle cingulate gyrus and supplementary motor 
area of patients treated with mirtazapine (Frodl, Scheuerecker et al. 2011). 
Another pharmaco-fMRI study investigated effects of agomelatine or placebo in depressed 
patients in contrast to healthy controls during an emotional self-referential task before and after 
short term (one week) and long term (seven weeks) treatments (Delaveau, Jabourian et al. 2016) 
Patients treated with agomelatine exhibited significant deactivations in the ventrolateral 
prefrontal cortex during self-referential processing after one week. Interestingly, after seven 
weeks, depressed patients showed significant increases in the activation of the ventral anterior 
cingulate cortex. This shows that agomelatine had short- and long-term effects on brain 
structures involved in anhedonia and emotional regulation of depressed patients. 
As described in the previous section, we could demonstrate statistically significant treatment 
effects (figure 24a, d, e and figure 28), but we could also not distinguish between the patient 
groups receiving agomelatine, escitalopram, mirtazapine or placebo. Again, the cause of this 
lack of differential results may be the small sample sizes in our four treatment groups or due to 
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unspecific treatment effects which were similar in all treatment groups. As described before, 
depressive symptoms deceased markedly during the first treatment week in all four treatment 
groups. The clinical course of placebo treated patients was not significantly different from 
patients receiving medication. Therefore, the changes seen in our fMRI investigation again may 
be interpreted as state markers reflecting the severity of the depressive disorder more than 
reflecting the specific modes of action of the used antidepressants. 
4.4. Correlation BOLD % signal change with severity of depression 
Exploratory correlations between the activations in our ROIs during specific contrasts and the 
clinical characteristics of the investigated major depressed patients were calculated using a two-
tailed test with the Spearman’s rank correlation coefficient. 
Untreated depressed patients showed a significant positive correlation of their depression status 
measured with the HAM-D21 scale with the activity in the right DLPFC as a reaction to angry 
emotional faces and to neutral faces. 
Because neurons located in the prefrontal cortex and especially in the DLPFC seem to 
selectively process face-specific information (SP, Wilson et al. 1997) and are involved in face 
perception (Dekowska, Kuniecki et al. 2008), the expected activation of the DLPFC in our face 
paradigm may be influenced by MDD and the resulting affective state. We are not able to 
confirm the reported association of MDD with a reduced activation in the DLPFC (MacNamara, 
Klumpp et al. 2017) which seem to be detectable especially in response to negative stimuli 
(Hamilton, Etkin et al. 2012) because we investigated only depressed patients. In addition, we 
could show a significantly increasing activation due to negative emotions (afraid vs. neutral 
faces) on the left side (figure 6a), while on the right side the activation after angry faces vs. 
baseline declines after one week of antidepressant treatment (figure 5). Functional 
abnormalities in the DLPFC representing possibly the neurophysiologic correlate of 
psychomotor slowing in MDD (Remijnse, Nielen et al. 2009) were confirmed also by other 
publications (Filkowski, Haas et al. 2017). Our investigation could confirm, that the activity in 
the DLPFC in response to negative facial stimuli was correlated significantly with the severity 
of the MDD measured with the HAM-D21 scale. After one week of treatment, we could confirm 
at least in some contrasts an increasing activity, but a significant correlation of the BOLD signal 
in the right DLPFC with the severity of the depressive syndrome was no longer detectable. 
Our patients showed a positive correlation of the activity in the right fusiform gyrus during the 
presentation of sad faces in comparison to baseline with the severity of depression before 
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starting the treatment. After one week of antidepressant treatment we could demonstrate a 
declining activity in the right fusiform gyrus (figure 7, figure 8). After one week of treatment 
the significant correlation could no longer be detected. 
The fusiform gyrus represents an important area in the ventral visual processing stream. In prior 
studies in adolescents suffering from MDD a bilateral hypoactivation in comparison to healthy 
controls was demonstrated (Ho, Zhang et al. 2016). Because more severe depression causes 
more activity in the fusiform gyrus in our study and due to the fact, that with lower HAM-D21 
scores after one week of antidepressant treatment also reduced activities in the fusiform gyrus 
were detected, these findings contradict the finding of Ho et al. demonstrating lower activation 
in depression. On the other hand, Robertson et al. reported a reduction in the fMRI BOLD signal 
in the right fusiform gyrus after successful treatment with the dopaminergic and noradrenergic 
antidepressant bupropione, which was even correlated with the HAM-D improvement pointing 
in same direction as our correlative analysis (Robertson, Wang et al. 2007). Also, another study 
in adult MDD patients suggested larger BOLD responses in the fusiform gyrus (here at the left 
side) as predictors of antidepressant treatment response to the SNRI venlafaxine (Frodl, 
Scheuerecker et al. 2011). 
In the left amygdala a reduction of the BOLD response to afraid faces vs. scrambled pictures 
was registered (figure 4a). In addition, this contrast was associated only after, but not before 
treatment with the severity of the depression. 
The amygdala activity in MDD has been reported to be increased after negative stimuli 
(Jaworska, Yang et al. 2015). This was confirmed especially in the left amygdala also in another 
study comparing MDD patients with healthy controls (Jenkins, Kassel et al. 2016). It was even 
reported, that more pronounced symptoms of the MDD are associated with more distinct 
decreases of amygdala activation (Anderson, Juhasz et al. 2011). Moreover, positive 
correlations of the amygdala activity with the severity of an MDD were reported from a study 
in both, adolescents and older adults (Mingtian, Shuqiao et al. 2012). Both findings confirm 
both our results of the reduced amygdala activity after short term treatment and the association 
with the severity of the MDD. In contrast, a more pronounced illness, represented by higher 
HAM-D scores on the day of our first fMRI scan, was not correlated with the level of amygdala 
activity. 
It can be summarized therefore, that the BOLD signal change during presentation of emotional 
and neutral faces in divergent ROIs such as the amygdala, the fusiform gyrus, and the DLPFC 
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are associated with the severity of MDD and may be state markers for the disease. The fact that 
these correlations are not consistently registered before and after short-term treatment may 
result from the limited power of the presented study or from a state dependent relationship 
before and after any treatment affecting the depressed state. 
4.5. Correlation BOLD % signal change with HPA-axis activity 
Brain areas corresponding to ROIs investigated in this study such as the hippocampus, the 
amygdala and the prefrontal cortex represent parts of the limbic system which may have a 
crucial impact on the regulation of the HPA axis. The hippocampus contains high levels of 
glucocorticoid receptors, is structurally connected with emotion-related brain regions such as 
the prefrontal cortex and amygdala, and regulates the HPA axis (Miller and Cohen 2001). 
Exposure to stress and activation of the HPA axis are associated with decreased activity in some 
of these regions (Pruessner, Dedovic et al. 2010). Therefore, MDD as a stress related disorder 
and the relief of depressive symptoms may be associated with the activity in these areas. The 
hippocampus contains glucocorticoid receptors and seems to provide a gateway to regulation 
mechanisms including also other interconnected brain regions such as the amygdala and the 
PFC (McEwen, Nasca et al. 2016). The amygdala stimulates CRH production and interacts also 
with the prefrontal cortex (Hakamata, Komi et al. 2017). One part of the PFC, the DLPFC 
mediates cognitive functions, including attentional control (Liu, Ge et al. 2017). 
Exploratory correlations between the activations in the predefined ROIs during specific 
contrasts and the activity of the HPA-axis determined using AUCs and peak values of combined 
Dex/CRH test before and after short term treatment with antidepressants or placebo were 
calculated using the two-tailed test with the Spearman’s rank correlation coefficient. The pre-
treatment Dex/CRH-test revealed only a significant negative correlation of the activity in the 
right DLPFC calculating the contrast between responses to afraid and happy facial pictures: the 
smaller the registered BOLD % signal change, the higher was the HPA-axis activity. Because 
MDD represents a chronic exposure to stress activating the HPA axis due to functional loss of 
negative feedback loops, it seems plausible, that we could register a decreased activity in the 
DLPFC (Pruessner, Dedovic et al. 2010) with more severe depression ratings, even if we could 
not provide the linking data of strong and direct correlations between the HPA axis activity and 
the HAM-D21 scores as a direct link. 
The post-treatment Dex/CRH-test results confirmed an even more pronounced relationship to 
the activation patterns in the predefined ROIs: Activity in the left hippocampus was inversely 
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correlated with cortisol secretion during contrasts between afraid vs. neutral as well as afraid 
vs. happy faces. The same was true for the right side during the contrasts between afraid and 
happy vs. neutral faces. On a structural level, these results are in line with a study describing 
the consequences of a loss of hippocampal function due to structural changes: hippocampus 
atrophy was related to both, HPA axis dysregulation and depression (O'Brien, Ames et al. 
1996). Also a study in patients suffering from structural brain damage including an uni- or 
bilateral involvement of the hippocampus suffered from disturbed HPA axis regulation with an 
abolished cortisol response to awakening (Buchanan, Kern et al. 2004). Also, hippocampal 
shape abnormalities which have been found in patients suffering from MDD were associated 
with changes in cortisol levels (Watanabe, Kakeda et al. 2017). Moreover, more sophisticated 
structural MRI investigations in MDD patients confirmed a negative association between 
cortisol levels and the volume of a hippocampal subfield (cornu ammonis 1-3, horn of ammon, 
hippocampus major) on the left side (Travis, Coupland et al. 2016). On a functional level our 
results are in line with an investigation confirming that not only structure, but also the activity 
of the hippocampus plays a major role in adaptive processes to stress: individuals reacting to 
acute stress with cortisol secretion showed higher hippocampal deactivation patterns (Khalili-
Mahani, Dedovic et al. 2010). Therefore, it seems plausible, that also the chronic stress of our 
MDD patients which includes chronic HPA axis hyperactivity is connected with reduced 
hippocampal activity. This was confirmed in our investigation with the negative correlation 
between cortisol secretion and hippocampal activity during the emotional faces task for the first 
time. 
The post-treatment activity of right DLPFC was negatively correlated with the BOLD % signal 
change in contrasts between happy, neutral and sad faces vs. scrambled pictures and due to 
contrasts between angry and neutral faces. This negative correlation of the activity during the 
first four contrasts with cortisol secretion seems to be in line with the regulatory function of the 
DLPFC receiving downstream signals from the hippocampus for cognitive and attentional 
functions described above (Liu, Ge et al. 2017). Surprisingly, the contrasts of angry and sad vs. 
happy faces, happy vs. neutral faces, and the contrasts between faces and scrambled pictures 
showed statistically significant positive correlations with the HPA axis activity. 
Notwithstanding, these positive correlations of the DLPFC activity during the latter described 
contrasts cannot be interpreted easily. No published studies can be found that are in line of this 
result, in addition, it contradicts in part the above described regulatory functions which were in 
line to the higher cortisol secretion associated with lower DLPFC BOLD signal during face 
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processing. Therefore, also statistical artifacts or accidental correlations independent of 
regulatory processes cannot be ruled out. 
The HPA axis activity during the post-treatment Dex/CRH-test was related and inversely 
correlated to the BOLD response during the presentation of afraid vs. happy or neutral faces in 
the right fusiform gyrus. 
The fusiform gyrus is considered as a brain region specialized for face perception (Weiner and 
Zilles 2016). Moreover, a microanatomical asymmetry seems to provide the anatomical 
correlate for a hemispheric specialization which supports the predominance of the right 
hemisphere for face processing (Chance, Sawyer et al. 2013). Because the amygdala influences 
the function of the fusiform gyrus during the perception of faces (Herrington, Taylor et al. 2011) 
and is itself influenced by projections from the hypothalamus which is regulating the HPA axis 
activity as described above, the negative correlation of the BOLD response of the right fusiform 
gyrus during the perception of emotional faces with the status of the HPA axis activity seems 
to be plausible, even if this finding has not been published elsewhere up to now. The amygdala 
mediates the HPA axis activity especially during the perception of threat-related stimuli such 
as afraid faces and during anxiety symptoms, but up to now the neural mechanisms facilitating 
these reactions were considered to be unclear (Di Iorio, Carey et al. 2017). Therefore, it cannot 
be ruled out that the regulating cascade from the processing of emotional faces in the fusiform 
gyrus may interact with amygdala and hippocampus in the processes of stress and HPA axis 
activity regulation. 
4.6. Limitations and strengths of the study 
Some limitations of the present study exist. First of all, the power of the study was calculated 
to detect changes of the fMRI BOLD signals before and after one week of antidepressant short-
term treatment. Further subdivisions of the patient sample, such as subgroup analyses of the 
four different treatment groups after randomization to investigate the differential developments 
of the BOLD signals, the clinical variables, and the results of the combined Dex/CRH tests may 
not have enough power to proceed beyond exploratory analyses.  
The second main limitation of the study was the use of three different scanner models due to 
the replacement of the old research scanner, the reconstruction, installation, and setup-time for 
the new research scanner, during which time we used a clinical scanner at the 
Universitätsklinikum Regensburg, and the new research scanner which was used to produce 
most of the fMRI data presented here. 
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A third limitation may be the occasional use of concomitant medication which was limited to 
lorazepam for agitation and zopiclone for insomnia and given only in standardized dosages. 
The short treatment time of only one week before the 2nd fMRI and Dex/CRH test may be 
viewed either as a weakness or as a strength of this study. It may be a weakness due to the 
limited therapeutic proceedings during antidepressant treatments. Full antidepressant effects 
usually can be reached after four to six weeks. At the same time it was planned as an advantage, 
because besides the clinical changes the fMRI and Dex/CRH data may possibly be used in later 
analyses to predict the later response to the divergent antidepressant treatments. 
A further weakness may be then the changes in therapeutic regimes which were possible after 
the first two weeks of treatment. These may induce a higher variability in the data, but were 
inevitable for the treated patients to avoid clinical disadvantages due to study participation. 
Clear strengths of the study were the randomization to the treatment groups, the placebo control 
group, the standardized treatment during the first two weeks of treatment including both fMRI 
investigations and both Dex/CRH tests. Moreover, it is a strength to follow up the clinical data 
of all patients up to remission and discharge from the hospital. 
The main advantage of the presented study is the combination of investigations including fMRI 
data using the emotional faces paradigm with high sensitivity tests for the HPA axis activity 
and clinical data. Further investigations not presented here will include also structural MRI 
scans, long resting state investigations, diffusor tensor imaging data, a battery of 
neuroinflammatory markers together with the status of Omega-3 polyunsaturated fatty acids, 
and the gut microbiome compositions. 
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5. Summary 
Background: Major Depressive Disorder (MDD) is a chronic stress related disorder 
characterized by depressed mood, by vegetative and cognitive symptoms. Imaging biomarkers 
may help to predict the impaired processing and regulation of emotions related to MDD and to 
antidepressant treatment response. Pharmaco neuroimaging and behavioral studies have shown 
that antidepressants can affect emotional processing very early after starting the treatment and 
independently from changes in subjective mood. Moreover, normalization of hypothalamus-
pituitary-adrenal (HPA) axis regulation, which is usually disturbed in MDD, is often associated 
with successful recovery from depression. Therefore, we investigated the relationship between 
neural activation before and after short term treatment with antidepressants and HPA axis 
activity in relation to clinical outcome in MDD patients. 
Methods: We investigated 33 in-patients admitted to the Department of Psychiatry and 
Psychotherapy, University of Regensburg, for the treatment of MDD. Firstly, we considered 
the evidence for a cognitive neuropsychological model of antidepressant drug action by 
employing pharmaco-fMRI (3T) in a double-blind randomized placebo-controlled design to 
investigate the effect of short-term treatment with escitalopram, mirtazapine, agomelatine or 
placebo on the BOLD signal change in predefined brain regions associated with a visual facial 
emotional and neutral stimulation task. Additionally, all patients received the same amount of 
psychotherapeutic support. 
Results: After one week of short-term treatment we detected a statistically significant reduction 
in the BOLD % signal change in the bilateral amygdala, right dorsolateral prefrontal cortex and 
the right fusiform gyrus during the presentation of facial emotional and neutral expressions. In 
a second evaluation, we compared medicated patients with unmedicated (placebo treated) 
patients. Here we could see significant effects in the described regions but could not detect 
significant differences between verum and placebo groups. After that, each treatment group was 
investigated separately and compared together. The results showed again statistically 
significant effects in the above described regions, but no significant differences between the 
treatment groups. The clinical outcome after one week of treatment showed a partial recovery 
of the patients with reduced scores in the Hamilton rating scale for depression together with 
and correlated with BOLD % signal change in some specific regions. Moreover, the activity of 
the HPA axis was reduced slightly. In addition, this reduction showed significant correlations 
with the BOLD % signal change in some of the regions of interest. 
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Discussion: The purpose of this study was to provide a better understanding of the interface 
between neural systems during antidepressant treatment, the short term effects of 
antidepressants on emotional processing, to bridge the gap between defined brain regions 
(amygdala, DLPFC, fusiform gyrus, hippocampus and insula) the fMRI BOLD signal, HPA 
axis hyperactivity, and the clinical status of major depressed patients. We could show that 
bilateral amygdala hyperactivities in depressed patients were reduced even after short term 
treatment. A trend to reduce and normalize also the activity in the right dorsolateral prefrontal 
cortex and in the right fusiform gyrus was consistent also with other fMRI studies. In addition, 
we could demonstrate a probable association between the HPA axis regulation and the activity 
in the brain regions of interest investigated in our study. We could demonstrate the onset of a 
normalization of the HPA axis activity, as well as the onset of clinical improvement after one 
week of treatment, but our study lacked statistic power to differentiate between our four 
treatment groups. In addition, it is possible that unspecific effects of counseling and the in-
patient treatment regimen outweigh any specific pharmacological treatment effects after only 
one week of antidepressant treatment. 
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3T 3 Tesla 
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5HT2a, 2c, 3 serotonin 2a, 2c, 3 (receptors) 
AC anterior commissure 
ACC anterior cingulate cortex 
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AKDEF Averaged Karolinska directed emotional faces 
ANOVA analysis of variance 
ASF a simple framework (toolbox) 
AUC area under the curve 
BA Brodmann’s area 
Bc baseline corrected 
BfArM Bundesinstitut für Arzneimittel und Medizinprodukte 
BMBF Bundesministerium für Bildung und Forschung 
BOLD blood oxygenation level-dependent 
CBT cognitive behavioral therapy 
CNS central nervous system 
CRH corticotropin releasing hormone 
Dex dexamethasone 
Df degrees of freedom 
DGPPN Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und 
Nervenheilkunde 
DLPFC dorsolateral prefrontal cortex 
DMN default mode network 
DST dexamethasone suppression test 
DTI diffusion tensor imaging 
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fMRI functional magnetic resonance imaging 
FWE family wise error 
GLM general linear model 
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HAM-D Hamilton rating scale for depression 
HPA hypothalamus-pituitary-adrenal 
HRF hemodynamic response function 
ICD international classification of diseases 
ICH International Council for Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use 
K-S Kolmogorov-Smirnov 
LPDF lateral prefrontal cortex 
M.I.N.I. Mini-International Neuropsychiatric Interview 
MarsBaR MARSeille Boîte À Région d’Intérêt (name of an SPM toolbox) 
MATLAB MATrix LABoratory 
MDD major depressive disorder 
MED medication 
min minute 
MNI Montreal Neurological Institute 
MPFC medial prefrontal cortex 
MRI magnetic resonance imaging 
MT1, 2 melatonin 1, 2 (receptors) 
NARI noradrenaline reuptake inhibitor 
n.s. not statistically significant 
OFC orbitofrontal cortex 
PCu precuneus 
PET positron emission tomography 
PFC prefrontal cortex 
PHG parahippocampal gyrus 
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ReML restricted maximum likelihood 
rmANOVA repeated measures ANOVA 
rTMS repetitive transcranial magnetic stimulation 
ROI region of interest 
s second 
SCG subcallosal cingulate gyrus 
SEM standard error of the mean 
SNRI selective noradrenalin and serotonin reuptake inhibitor 
SPM statistical parametrical mapping 
SPSS Statistical Package for the Social Sciences 
SSRI selective serotonin reuptake inhibitor 
STD standard deviation 
TR time repetition 
Vs. Versus 
WHO world health organization 
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